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Stellingen behorende bij het proefschrift: 
Idiopathic Sudden Sensorineural Hearing Loss 
1 .  ISSHL: een moeilijke oor-zaak. 
2 .  Zowel het v66rkomen als de  gevolgen van ISSHL worden onderschat. 
3 .  O p  macroniveau wordt d e  prognose van ISSHL gunstig bei"nvloed door het 
structureel toepassen van de stemvork bij ooronderzoek in de eerste lijn. 
4. ISSHL is behalve een otological emergency ook een radiological emergency. 
5 .  Een virale labyrinthitis lijkt een belangrijke rol te spelen i n  de pathofysiologie van 
ISSHL. 
6 .  Het is moeilijk om een goed oordeel te geven over een onderwerp waarover iedereen 
al een mening heeft. 
7 .  Het uitvoeren van multicentre c+inical trials wordt bemoeilijkt door de noodzaak om 
het onderzoeksprotocol in ieder centrum door een medisch ethische commissie te 
Iaten beoordelen. Ook de daarvoor geeiste beoordelingsvergoeding moet ter discussie 
worden gesteld. 
8 .  Verhalen over het verwijderen van het nervus vestibularis schwannoom en over de 
opbrengst van een dagje vissen lijken vaak op elkaar: bij beide wordt op den duur de 
centimeter korter dan hij was. 
9 .  In een tijd waarin het uitdragen van medisch technische hoogstandjes regel i s  en 
ziekenhuizen als een kathedraal het stadsbeeld markeren wordt de maakbaarheid van 
gezondheid en welbevinden gemakkelijk overschat. 
1 0. Opkomst en neergang van "Reality TV" zijn intrinsiek aan de verzorgingsstaat. 
1 1. Het veiligheidsideaa1, zoals wordt gesuggereerd door het inbouwen van steeds meer 
airbags in auto's wordt pas bereikt a1s het aangereden automobiel vanzelf ter recycling 
zweeft. 
12.  Shakespeare waarschuwde al voor de toxiciteit van oordruppe1s. 
(Hamlet l.v.65-82, N Eng! J Med. 1 982; 307: 259-6 1 / 153 1 )  
13 .  Prosper Meniere: ze1fs over de spelling van zijn naam bestaat geen consensus. 
(Laryng Rhino! Otol. 1984; 63: 38 1 -5) 
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Hearing is a primary prereqUisite for interaction with our environment. Loss of 
hearing strikes in the very core of our existence. In sudden hearing loss, its abruptness 
makes eventual acceptance even more difficult. The sensorineural nature of the 
hearing loss seriously limits potential therapeutic options, in contrast to a conductive 
hearing loss. For a small minority of sudden sensorineural hearing losses an 
identifiable cause exists, in some cases giving a therapeutic directive. The idiopathic 
character of the sudden sensorineural hearing loss discussed in this thesis comprises 
the majority of sudden sensorineural hearing losses and does not reveal directives 
towards its etiology or treatment. Due to its enigmatic etiology and its disappointing 
treatment results, Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is 
confronting the clinician with an intricate problem. 
Only in the context of history some relief can be found: the sense of hearing has been 
puzzling physicians throughout the past millennia1.2. The earliest medical writing is to 
be found in Egyptian papyri, the most famous of which is the Papyrus Ebers, sold by 
the citizens of Luxor to Professor Georg Ebers of Leipzig in 1872. It has been 
written about 1550 BC and consists of lists of empiric remedies. One of the 
prescriptions is for deafness: 
"For an ear that hears badly- red lead, and resin from the am-tree, 
grind to powder, rub in fresh olive oil and apply to the ear". 
The school of Salerno, being the first medical school in Europe, was at its heydays 
during the great crusades (1096-1270). Its "Regimen Sanitatis Salernitanum" 
summarizes probably one of the earliest differential diagnoses of sudden hearing loss: 
Our hearing is a choice and dainty sense, 
And hard to mend, yet soon it may be marred. 
These are the things that breed it most offence 
To sleep on stomach full, and drinking Izard: 
Blows, falls and noise, and fasting, violence, 
Great heat, and sudden cooling afterward: 
All these, as is by sundry proofs appearing, 
Breed tingling in the ears and hurt out hearing. 
Otological history did not pass by Groningen completely. The first textbook of 
otology "De Auditus Instrumento" was written in 1572 by Volcher Coiter (1534-
1600), who originated from Groningen. He summarized his knowledge regarding the 
physiology of hearing as follows: 
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"The main function of the tympanic membrane is to protect the middle ear and 
to preserve the purity of the 'Aer Implantatus ', which conducts sound to the 
cochlea. This cavity also contains air and acts like a resonator, increasing the 
sound, which then impinges on the ramifications of the auditory nerves". 
The term 'Aer Implantatus' ongmates from an ancient belief that this air was 
implanted by the Maker, but according to Coiter, it originated in the external ear and 
was filtered and warmed in the mastoid cells. 
One of the first descriptions of sudden sensorineural hearing loss can be ascribed to 
Prosper Meniere ( 1799-1862), thereby adding another controversy to his famous case 
history. Meniere reported to the Academy of Medicine in Paris on January 8th, 1861 
as follows: 
"/ have spoken elsewhere, a long time ago, of a girl who - journeying on the 
box-seat of a stage coach - became as a result of the severe cold suddenly and 
completely deaf". 
The case was subsequently published in the Gazette Medicale de Paris on September 
2 1st, 1861. 
In our era, publications regarding sudden hearing loss have multiplied. In 1922, 
Kobrak3 described a case of sudden hearing loss for which no explanation could be 
given. In 1933, Colett4 reported to the Third Congress of the Societas Oto-Rhino­
Laryngologica Latina, and put forward "serous meningitis" to be responsible for the 
hearing loss. In 1944, De K.leijn5 proposed a vascular incident to cause sudden 
sensorineural hearing loss. In 1957, Bierman defended his thesis entitled "Sudden 
Perceptive Deafness" in Leiden, appreciating a viral role in the pathogenesis of 
ISSHL6• Since then, considerable efforts have been made by various authors to 
unravel the pathophysiology of ISSHL. Today, the etiology of ISSHL has not been 
elucidated and no truly successful therapeutic regimen exists. 
ISSHL is probably resisting these efforts because the two approaches often applied in 
medical science are bound to fail in ISSHO: empirical control of its therapy is 
hindered by its low incidence, and although the logical approach has elicited 
divergent hypotheses on its pathophysiology, these are hard to verify in the delicate, 
closed compartment formed by the inner ear. 
Thus, modesty seems obligatory when attempting to stretch these limitations which 
are implicit to medical science itself. In ISSHL, determination in establishing its 
pathophysiology and therapy is justifiable because every ENT-surgeon is confronted 
at a regular interval with patients who have, for no apparent reason, suddenly lost 
their hearing. They demand a proper explanation and are disappointed, as we are, by 
treatment results. 
Any enigmatic disease has been subject to speculation on its pathophysiology and the 
panacea for ISSHL has been abandoned as often as it has been presented. 
In this thesis, a meta-analysis of recent literature is performed on etiology and 
treatment of ISSHL. Etiological, diagnostic and therapeutical issues are investigated 
by an epidemiological survey among Dutch and Flemish ENT-surgeons. Based on 
these results a hypothesis concerning etiology and treatment of ISSHL is deduced and 
subsequently tested in an animal model. The implications of this hypothesis are 
verified in clinical practice. The two main limitations of ISSHL research mentioned 
previously are encountered as follows: insight in labyrinthine pathology of ISSHL 
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without disturbing the integrity of the inner ear might be provided by using modern 
MRI techniques. By using a multi-center study design, with the collaboration of many 
ENT-surgeons, incidence problems might be solved. 
Outline of the thesis 
Current hypotheses regarding the etiology of ISSHL with their supportive findings are 
reviewed in Chapter 2. Accumulating circumstantial evidence implies a subclinical 
viral labyrinthitis in explaining a majority of ISSHL cases. This hypothesis is 
assessed further in this thesis. 
Divergent therapeutic strategies have been applied in ISSHL. These are reviewed in 
Chapter 3. Considerable difficulties arise when evaluating therapy of ISSHL. Among 
them its inconsistent definition, its tendency to recover spontaneously and its low 
incidence. These impede validation of many therapeutic strategies in ISSHL. 
Research efforts are warranted by their applicability in daily practice. From a survey 
on ISSHL in the Netherlands and Flanders, an inventory of diagnostic and therapeutic 
strategies in ISST-U. is made and some epidemiological estimates can be derived. 
These are reported in Chapter 4 .  
In  Chapter 5, an  effort to gain further insight in the pathogenesis of  ISSHL by  using 
an animal model is described. Experimental herpes simplex viral labyrinthitis is 
elicited in the guinea pig and cochlear function and cochlear structure are evaluated. 
In Chapter 6, the influence of treatment on this animal model is assessed, using 
prednisolone and the antiviral drug aciclovir (Zovirax®), both as a monotherapy and 
as a combination therapy. 
The application of modern imaging techniques might reveal labyrinthine pathology in 
ISSHL. Thirty-six patients suffering ISSHL were studied by Magnetic Resonance 
Imaging. Our findings are discussed in Chapter 7. 
The verification of the therapeutic value of the combined treatment with antiviral and 
anti-inflammatory therapy in ISSHL patients required the combined effort of many 
Dutch and Flemish ENT -surgeons and their patients. In Chapter 8 the results of a 
prospective multicenter clinical trial regarding antiviral and anti-inflammatory 
therapy of ISSHL are reported. 
In Chapter 9, the results of the study are summarized and future prospectives with 
regard to further investigations are discussed. 
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THE ETIOLOGY OF IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS: 
a review of the literature 
Stokroos RJ, Albers FWJ. The etiology of idiopathic sudden sensorineural hearing 
loss: a review of the literature. Acta ORL Belg 1996; 50: 69-76. 
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Introduction 
Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is a shocking event to the 
patient and a puzzling condition to the clinician, because its etiology has not been 
elucidated yet and therefore treatment is empirical. This review was designed to 
evaluate reports concerning the etiology of ISSHL critically. The implications of the 
results with regard to the pathophysiology of ISSHL and the possibilities for future 
research are discussed. 
No consensus exists in literature on the definition of ISSHL. In order to conduct an 
adequate review on the etiology of ISSHL we used the following definition: 
Inclusion criteria: 
1 .  Sensorineural hearing impairment of unknown etiology. 
2. Hearing impairment occurring within 24 hours. 
3. Hearing impairment is nonfluctuating. 
4 .  Hearing impairment averages at least 30 dB HL for three subsequent one 
octave steps in frequency in the standard pure-tone audiogram. 
Exclusion criteria: 
I. Identification of specific causes of sensorineural hearing impairment using 
common clinical, laboratory and radiological investigations. 
2. A history of fluctuating hearing impairment. 
3. A compromised otological history. 
The symptomatology and natural course of ISSHL approximating our definition has 
been described by Mattox and Simmons 1 • They described ISSHL in 89 ears of 88 
patients. Mean age was 46 years, varying from 10 to 79 years. Hearing impairment 
most often developed in a few hours, some hearing losses were present at awakening. 
Many patients complained about fullness or pain in the ear. Tinnitus was frequently 
noticed afterwards, but in some cases it preceded the hearing loss. Some patients 
experienced postural instability or vertigo. Spontaneous recovery to a functional 
hearing level was found in 65% of cases. Prognosis was related to the severity of the 
initial hearing loss and vestibular involvement. Prognosis also seemed to be related 
to audiogram contour. Downsloping audiograms indicating pathology in the base of 
the cochlea were associated with a less favourable prognosis compared to upsloping 
audiograms, indicating damage to the apex of the cochlea. Therefore, it was 
concluded that recovery was better at the apex than at the base of the cochlea. 
The four most commonly encountered hypotheses trying to explain Idiopathic Sudden 
Sensorineural Hearing Loss are: 
a. Impairment of labyrinthine blood supply, 
b. Inner ear membrane ruptures, 
c. Viral infection of the labyrinth, 
d. Autoimmune mediated cochlear malfunction. 
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Combinations of these hypotheses have been postulated as a possible cause of 
ISSHL in the literature. 
Review 
We selected a combination of clinical and experimental characteristics commonly 
used as evidence for a certain etiology of ISSHL. The literature was reviewed using 
the following characteristics: 
a. Clinical findings, 
b. Laboratory, 
c. Radiology, 
d. Post mortem temporal bone histopathology, 
e. Experimental evidence. 
Studies listed in table 1 were included since the definition of ISSHL essentially 
approximated our inclusion and exclusion criteria. These studies contained a well­
documented patient group and/or a clear experimental design. 
Table 1: Characteristi cs versus possible etiology of ISSHL as described in the literature 
Vascular Membrane Viral Autoimmune 
impairment rupture infection mediated 
Clinical evidence Kitamura' Nomura16 Van Dishoeck21 M cCabe" 
Plasse3 Simmons" Kobayashi " Kanzaki44 





Laboratory Einer• Vel tri '• Elies41 
Rowson"' Veldman'6 
Wilson3u2 
Radiology Albers10 Albers"' 




Experimental Igarashin Simmons•• Rarey3• Yamanobe47 
evidence Perlman" Axelsson 20 Nomura"' 





Kitamura and Berrebf described a patient suffering from sudden hearing Joss of his 
right ear, with simultaneous development of hemiparesis and cranial nerve paralysis. 
Autopsy, performed 1 7  days later, showed severe arteriosclerosis, thrombosis of right 
basilar and vertebral arteries, and severe degeneration of the cochleovestibular 
cellular structures. 
Plasse et al.3 described unilateral sudden hearing Joss postoperatively in 7 of 7000 
patients who underwent cardiopulmonary bypass surgery. Cervantes Escarcega4 
described unilateral sudden hearing loss in 1 1  of 5975 patients who underwent open 
heart surgery. Both authors hold microemboli responsible for the hearing losses. 
Ogawa and Kanzak:i5 reported 3 patients suffering from aplastic anaemia, developing 
sudden hearing Joss just prior to, or at the onset of thrombocytopenia. It is speculated 
that inner ear haemorrhage is responsible for the sudden hearing Joss in these cases. 
Sudden hearing loss has also been reported in leukemia by Sando and Egami6, 
Schuknecht et al.7 and Yabe et al.8 On post mortem analysis, haemorrhage, after a 
period of 30 days followed by fibrosis and ossification was found in these inner ears. 
laboratory 
Einer et al.9 performed a prospective evaluation of pathological haemostatic 
mechanisms in sudden hearing Joss in 32 consecutive patients with sudden hearing 
loss. Twenty-eight healthy individuals functioned as a control group. They observed 
non-significant isolated aberrations in the haemostatic pathway, considered too 
discrete to be relevant for a causal role in sudden hearing loss. 
radiology 
Albers et al.10 examined 5 patients suffering ISSHL using a combination of high 
resolution computed tomography and special magnetic resonance imaging techniques. 
By three-dimensional constructive interference in steady state magnetic resonance 
imaging (3 DFf-CISS MRI) excellent visualization of the membranous labyrinth was 
obtained. No fibrous or osseous obliteration of the intralabyrinthine fluid spaces was 
observed in any of the investigated temporal bones. This obliteration was expected if 
impairment of labyrinthine blood supply would have Jed to ISSHL. 
temporal bone histopathology 
Belal11 described temporal bone histology of seven patients who underwent removal 
of an acoustic neuroma, in which the internal auditory artery was ligated. An autopsy 
was performed varying from one day to eleven years postoperatively. Severe cochlear 
degeneration was found, progressing to complete ossification of the cochlea one year 
after surgery. Yoon et al.12 reported fibrosis and new hone formation in two cases in 
which sudden hearing Joss was associated with vascular insult. 
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ex perimental evidence 
Experimental efforts to prove a vascular etiology have been done by Igarashi et a!Y, 
Perlman et al. 14 and Suga et al.'5. 
Igarashi 13  produced rnicroembolization of the cochlea in dogs. This caused functional 
and histopathological damage to the cochlea, resulting in fibrous connective tissue 
proliferation, followed four months later by ossification of the cochlea. Perlman 14 
surgically induced both arterial and venous occlusion of the guinea pig cochlea. Soon 
afterwards, extensive cochlear cellular destruction was observed, followed after one 
week by fibrosis and later by ossification of the cochlea. Suga15 induced 
microembolization of the cochlea in guinea pigs by injecting a significant amount of 
barium sulfate into the vertebral artery. He sometimes found the blood flow to 
recover, but the cochlear potential disappeared without recovery. Adding vasodilators 
did not change these findings. Short term histological examination of the cochlea 
showed mainly barium sulfate particles, but after a few weeks atrophy, fibrosis and 
ossification was seen in the cochlea. 
Membrane ruptures 
clinical evidence 
Direct or indirect trauma to the inner ear membranes can lead to a perilymph fistula. 
Nomura16 ascribed spontaneous perilymph fistulas to inadequate control mechanisms 
of cerebrospinal fluid pressure fluctuations when performing activities such as nose 
blowing or physical exercise. The perilymph fistula results in dizziness or 
disequilibrium and hearing loss. If the fistula does not close spontaneously, 
exploratory tympanotomy should be performed. 
Simmons 17 postulated inner ear membrane breaks as a possible cause of ISSHL. He 
explained sudden hearing loss over a broad frequency range by mixing of endo- and 
perilymph through a rupture of Reissner's membrane. Upon healing of this rupture, 
ionic equilibrium was reinstalled and hearing recovered. A small dip in the 
audiogram located the supposed membrane rupture. The inner ear membrane rupture 
was associated with a perilymph fistula to the middle ear. This hypothesis was 
supported by three case reports. Only the first case report slightly approximated our 
definition of ISSHL, the other two patients did not suffer idiopathic hearing losses 
but barotraumata. In all three cases a perilymph fistula was patched. No temporal 
bone histology was presented to support this hypothesis. Gussen 18 described two 
patients possibly having a double membrane break, but these cases did not match our 
definition of ISSHL. 
ex perimental evidence 
Experimental evidence suggests that perilymph leakage as a result from round or oval 
window rupture alone does not cause profound hearing Ioss 19•20• 
Oshiro et al.2 1 reported that the total hearing loss caused by simultaneous rupture of 
Reissner's membrane and the round window was larger than the sum of those caused 
separately. 
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Gyo and coworkers22 found that simultaneous rupture of Reissner's membrane in the 
second tum of the cochlea and the round window in guinea pigs showed a larger 
increase in action potential threshold than did the control ears with only round 
window rupture. This threshold shift was not observed when Reissner's membrane 
was ruptured at other turns. 
Viral infection 
clinical evidence 
Van Dishoeck23 reported a preceding respiratory infection in 30-40% of patients with 
ISSHL and suggested viral infection as a possible cause of ISSHL. Mattox and 
Simmons1 described the natural history of ISSHL in 88 patients. Twenty-eight 
percent had a history of an upper respiratory infection within one month before 
ISSHL occurred. Infections by several viruses such as mumps, measles, rubella, and 
herpes are known causes of acute sensorineural hearing loss24·25• Pyykko et af6 
identified human Spumaretrovirus as a possible cause of ISSHL. These infections, 
causing acute sensorineural hearing loss may sometimes follow an otherwise 
asymptomatic clinical course27• Liao et al�8 described similarities in the recovery of 
hearing loss induced by Lassa virus and recovery of ISSHL. 
laboratory 
Veltri et a1.29 surveyed 77 patients with ISSHL and found seroconversion in 65% 
(4 9177). Multiple agents were involved in 24 of 4 9  cases. Rowson et al.30 and Wilson 
et a!. 31 reported similar findings. 
Wilson32 observed herpes seroconversion in association with sudden hearing loss. 
The herpes seroconversion often occurred in association with other viral titer 
changes. 
radiology 
Albers et a!. 10 examined 5 patients suffering ISSHL using a combination of high 
resolution computed tomography and special magnetic resonance imaging techniques. 
The results of this study support a viral pathogenesis of ISSHL. 
temporal bone histopathology 
Schuknecht et al.33•34·35 presented temporal bone histology of 12 patients having 
suffered from ISSHL. In 6 of these patients viral upper respiratory infection 
coexisted. Atrophy of the organ of Corti and tectorial membrane, more outspoken in 
the basal coil and diminishing towards the apex was the most striking feature. The 
vestibular labyrinth and stria vascularis were less involved. No damage to vascular or 
neural structures was found. No fibrosis or ossification was found. No perilymph 
fistulas or signs of previous membrane breaks were seen. The contralateral (healthy) 
ears functioned as a matched control group. The authors found cochlear changes 
resembling those found after hearing loss associated with rubella or mumps. Yoon et 
al.36 and Sando et al.37 reported similar observations. 
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Fukuda and coworkers38 postulated reactivation of latent viral infection of the spiral 
ganglion as a possible explanation for ISSHL. In five patients, without a history of 
recent herpes infection or ISSHL, herpes simplex virus type 1 DNA was found in all 
of 10 spiral ganglia in post mortem analysis using polymerase chain reaction.  
Newborn spiral ganglia were negative for HSV- 1 DNA. The exact mechanism 
operational in the possible reactivation of latent viral infection remains obscure. 
ex perimental evidence 
Rarey et al.39 inoculated ferrets with influenza viruses and induced conductive and/or 
sensorineural hearing losses. 
Nomura et al.40 inoculated guinea pig inner ears with herpes simplex virus. The 
histopathological characteristics were compared to the histopathological findings of 
the temporal bones of a woman who suffered sudden deafness 33 years before 
decease. Changes in experimentally induced herpes simplex virus labyrinthitis 
resembled those found in the human temporal bones after sudden deafness. 
Hirai4 1 inoculated guinea pigs with Sendai virus. Cochlear histopathology resembled 
descriptions of temporal bones in ISSHL. The resemblance of labyrinthine 
histopathology induced in animal experiments and temporal bone histopathology 
found in post mortem investigation of patients having suffered ISSHL has also been 
reported by Fukuda et al.42 
Autoimmune labyrinthitis 
clinical evidence 
McCabe43 described 8 cases of autoimmune sensorineural hearing loss. Kanzaki44 
interpreted these cases as patients suffering from atypical Cogan's syndrome or 
variants of polyarthritis nodosa. 
laboratory 
Elies and Plester45 proposed an autoimmune pathogenesis for various inner ear 
diseases. They found a raised CSF total protein and positive tissue auto-antibodies in 
patients suffering from Meniere's disease, sudden deafness and chronic progressive 
sensorineural hearing loss. 
Veldman et al.46 analyzed sera from 3 1  sudden deafness patients using Western Blot 
assays with heterologous swine inner ear antigen and protein extracts of other organs. 
In 65% of patients cross reacting antibodies were found, indicating an autoimmune 
origin. 
ex perimental evidence 
Yamanobe and Harris47 tried to identify the spontaneous course of experimental 
autoimmune labyrinthitis induced in guinea pigs. They injected processed 
homogenized bovine temporal bones as "crude inner ear antigen" and measured 
hearing threshold shifts, which never completely recovered. Histology of the cochlea 
showed a lymphocyte and poly-morphonucleocyte cellular infiltration in the inner ear, 
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with some spiral ganglion cell degeneration, thus suggesting a possible role for the 
cellular immunity in inducing hearing loss. 
Discussion and conclusions 
Vascular impairment 
A vascular etiology for ISSHL is attractive because its abrupt onset resembles other 
vascular catastrophes in the central nervous system. Sudden hearing loss is observed 
affer cardiac surgery, in which microembolism in the cochlea is a probable but 
unproven pathogenesis. However, the described clinical cases do not fulfill entirely 
the proposed definition of ISSHL with regard to the pre-existing history of 
arteriosclerosis. 
Experimentally induced hearing losses of vascular origin are predominantly 
irreversible. This is in contrast to ISSHL, where spontaneous recovery rates are 
reported between 45-65%1.48. Fibrosis and ossification of the cochlea, reported after 
experimentally produced impaired blood supply or by known infarction of the 
cochlea, were not found in post mortem temporal bone examination3014, or by 
imaging techniques, in patients with ISSHL10• 
A wide variation in age is found in ISSHL patients, not excluding childhood (Ullrich 
and Aurbach49). Often these patients have no evidence of chronic vascular disease 
and are otherwise healthy. No cardiovascular risk factors differentiating ISSHL 
patients from normal subjects could be identified (Schmolke et al .50, Preyer et al.s'). 
In the literature, we find insufficient clinical and experimental evidence to hold a 
vascular cause responsible for idiopathic sudden sensorineural hearing loss. 
Inner ear membrane ruptures 
Rupture of inner ear membranes is an interesting hypothesis explaining the 
suddenness and spontaneous recovery found in ISSHL. Clinical evidence is limited to 
one case report, which refers to a perilymph fistula, which is not in accordance with 
the definition of idiopathic sudden sensorineural hearing loss. 
Although severe hearing loss can be provoked experimentally by inducing double 
membrane breaks, the question remains if these breaks occur spontaneously in 
ISSHL. Temporal bone histology of well-documented ISSHL patients did not show 
evidence of (previous) membrane breaks. The inner ear membrane break hypothesis 
therefore lacks convincing clinical and histopathological evidence. 
Viral infection 
Viral upper respiratory infection is frequently reported in ISSHL patients, but also 
occurs often in the normal population. A viral etiology of ISSHL is supported by 
histopathological studies of the cochlea in ISSHL in which pathological changes 
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resemble those found in known labyrinthine viral infection and in experimentally 
induced viral infection. Imaging studies of the inner ear in ISSHL by Albers et al. 10 
support these findings. 
The presence of latent neurotropic herpes viruses in the spiral ganglia of 
asymptomatic individuals, and the rise in herpes titers together with seroconversions 
for other viruses in ISSHL makes reactivation of latent neurotropic viruses in the 
cochlea of ISSHL patients a most interesting hypothesis. After reviewing the 
literature we find this etiology worth to be investigated further. 
Autoimmune labyrinthitis 
Autoimmune labyrinthitis is sometimes proposed as an explanation of ISSHL, 
although evidence is so far circumstantial. The main disadvantage of this theory is the 
inability to explain the suddenness of ISSHL in otherwise healthy individuals, instead 
of the relapses and remissions observed in the clinical course of autoimmune 
diseases. Patients suffering from ISSHL have no systemic manifestations of 
autoimmune disease. Temporal bone histopathology after experimentally produced 
autoimmune cochleitis does not resemble histology found after ISSHL. In the 
literature we found insufficient evidence to accept or reject autoimmune disease as a 
cause of iSSHL. 
After reviewing the literature on the etiology of ISSHL we find impairment of 
vascularization and inner ear membrane ruptures not likely to play a major role in 
causing ISSHL, according to our proposed definition of ISSHL. We find insufficient 
evidence for an underlying autoimmune disease and therefore we acknowledge viral 
labyrinthine infection as being responsible for an important proportion of idiopathic 
sudden sensorineural hearing losses. This hypothesis needs further attention, not only 
in research but also in therapy of ISSHL. 
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Introduction 
Treatment of Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is empirical, 
because the etiology of the hearing loss has not been elucidated yet. Many strategies 
for treatment of ISSHL have been proposed over the years. This reflects the lack of a 
convincing successful regimen1 • Evaluating the success of a treatment modus is 
difficult because its performance has to be better than the high spontaneous recovery 
rate of ISSHL, reported between 45-65%2•3• In addition, studies containing sufficient 
patients are relatively scarce, due to the low incidence of ISSHL. 
For an effective investigation of the various treatment modalities consensus on the 
definition of ISSHL is obligatory. In chapter 14 we proposed the following definition 
of iSSHL. 
Inclusion criteria: 
1 .  Sensorineural hearing impairment of unknown etiology. 
2. Hearing impairment occurring within 24 hours. 
3. Hearing impairment is nonfluctuating. 
4. Hearing impairment averages at least 30 dB for three subsequent one octave 
steps in frequency in the standard pure-tone audiogram. 
Exclusion criteria: 
l .  Specific causes of sensorineural hearing impairment which can be identified 
using common clinical, laboratory and radiological investigations. 
2. A history of fluctuating hearing impairment. 
3. A compromised otological history. 
Most treatment protocols are based on one or more of the following strategies: 
a. Optimizing cochlear blood supply, 
b. Anti-inflammatory medication, 
c. Miscellaneous treatment. 
We reviewed the literature and evaluated whether one of the above strategies was 
effective in achieving hearing improvement in ISSHL according to our definition. 
The studies were analyzed with regard to the requirements of a clinical drug trial: 
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1. Comparativeness: the results obtained in the group of patients receiving the 
drug under study have to be compared to those obtained in a reference group 
of patients, for example receiving no therapy. 
2. Internal validity: the methodology used should allow a good estimate of the 
therapy-bound effect5• The methods used to ensure internal validity are 
randomization, double-blinding and imply a prospective study design. 
3. External validity: generalization of the results is possible by the strict 
definition of the disease according to the inclusion and exclusion criteria. 
Review 
I. Optimizing cochlear blood supply 
A. Clinical studies (Table 1) 
Kronenberg et al.6 evaluated the ability of procain hydrochloride, a vasodilator, and 
dextran (Rheomacrodex0), a plasma expander decreasing blood viscosity, to achieve 
hearing improvement in ISSHL. They performed a prospective randomized double 
blind clinical study of 27 ISSHL patients. Thirteen patients received procain 
hydrochloride and dextran, 14 patients received placebo. No significant differences in 
hearing improvement were found between both groups. The definition of ISSHL in 
this study approximated ours, the study design fulfills our requirements concerning 
comparativeness, internal and external validity. 
Kubo et al.7 performed a prospective paired double blind clinical trial comparing two 
treatment regimes in 162 ISSHL patients. 80 patients received defibrinogenation­
therapy with batroxobin (Defibrogenase0), a thrombinlike venom enzyme decreasing 
fibrinogen levels and thus reducing blood viscosity. 82 patients received 
betamethazone (Celestone®), a glucocorticosteroid. Hearing recovery was measured 
using a four point recovery scale. In the batroxobin treated group recovery was 
57.3%. In the betamethasone treated group recovery was 38.7%. This difference was 
statistically significant. 
Three years later, Shiraishi et al.8 reported results of the same study again, now 
comparing absolute values for hearing threshold levels instead of the former used 
four point hearing recovery scale. The batroxobin treated group consisted of 82, the 
betamethazone treated group of 86 patients. In achieving hearing recovery, 
defibrinogenase therapy performed slightly better (p < 0.1) when evaluated two 
weeks after starting therapy, thus seemed to achieve faster recovery than 
betamethazone. When evaluated after finishing treatment, performance of both 
treatment modalities was comparable. The use of absolute hearing threshold levels 
instead of allocating patients to a four point recovery scale made differences between 
both treatment modalities less clear. In this study, the definition of ISSHL 
approximated ours, it meets our standards on internal validity but since no 
comparison to the spontaneous recovery rate of ISSHL was made, comparativeness is 
questionable. 
Probst et al.9 treated ISSHL with dextran and pentoxifillin 
(Trental®), increasing red cell deformity and thereby lowering blood viscosity. The 
study was designed as a placebo controlled, randomized, double blind clinical trial. 
Patients were divided in three groups; the first (n = 67) received a placebo, the second 
(n = 53) received pentoxyfillin only, the third (n = 64) received both dextran and 
pentoxifillin. Absolute hearing gains were compared. No significant differences in 
hearing gain were found between these treatment groups. The definition of ISSHL in 
this study approximated ours, the study design fulfills our requirements concerning 
comparativeness, internal and external validity. 
Wissen and Aziz10 treated 112 patients suffering from ISSHL. Treatment results were 
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evaluated retrospectively. Sixty-nine patients were treated with dextran and 
pentoxifillin. Twenty-seven were treated with dextran and the vasodilators nicotic 
acid and novocain. Sixteen were treated with nicotic acid and novocain. No 
significant differences in hearing improvement were found using these treatment 
modalities. ISSHL is not well defined in this study, and its design did not fulfill our 
criteria concerning comparativeness and internal validity. 
Sudden hearing loss was treated with fibrinolysis using rt-PA (recombinant tissue­
type plasminogen activator, Actilyse®) by Hagen1 1 • Twelve patients suffering sudden 
hearing loss without vestibular symptoms were treated using rt-PA. In 7 patients, 
hearing was restored, in 3 patients some hearing improvement was obtained, two 
patients remained deaf. Based on this study, the authors do not recommend rt-PA as a 
treatment modality of ISSHL. Since the study lacked a control group, they find it 
difficult to distinguish between the therapy bound effect and the spontaneous 
recovery rate of ISSHL which can be expected slightly higher than average in this 
prognostically favourable patient selection. The study design did not fulfill our 
criteria concerning comparativeness and internal validity. 
Wilkins, Mattox and Lyles 12 performed a retrospective evaluation of a "shotgun" 
regimen for sudden hearing loss, consisting of the diuretic dyazide, the vasodilator 
histamine phosphate, the glucocorticosteroid dexamethazone (Decadron°), the 
iodinated dye used in radiologic studies diatrizoate meglumine (Hypaque®), the 
vasodilator nicotic acid (Nicobid61), the plasma expander dextran and inhalations of a 
5% carbogen I 95% oxygen gas mixture, supposed to improve cochlear blood flow. 
Hundred-twelve ears of 1 09 patients were evaluated. Thirty percent received the 
entire protocol, 70% received a varied part of the protocol. No significant difference 
in hearing recovery was found between these two groups. Of all patients, 26% 
achieved a complete recovery, 26-28% a partial recovery and 46-48% showed no 
response to treatment. The ability of each individual drug to produce hearing recovery 
was evaluated. No significant effects were found, except for diuretics, which caused a 
worse outcome in hearing recovery. A placebo treated or no treatment control group 
was not included in this study. The results fall within the range of spontaneous 
complete or good recovery reported in the literature when no treatment is given. In 
this design, we question comparativeness, internal and external validity. 
Koehn and Nickol 1 J treated 100 patients suffering sudden hearing loss with dextran, 
diazepam (Valium®) and vitamins A, B, C and E and added naftidrofuryl 
(Dusodril®) in half of the patients. Naftidrofuryl has antiserotinergic and therefore 
vasodilatory properties. No diagnostic criteria of ISSHL were given. Treatment 
results were analyzed retrospectively. Patients were divided in three age groups 
(under 30, 30-60 and over 60 years.) Naftidrofuryl treated patients achieved better 
hearing recovery in the middle aged group (p < 0.01 ). This study design did not meet 
our criteria on comparativeness, internal validity and external validity. 
Laskawi et al. 14 performed a prospectively randomized clinical trial in 1 5 1  ISSHL 
patients, comparing naftidrofuryl and pentoxyfillin, both in combination with 
hydrocortisone and dextran. No difference between both treatment modalities was 
found. Since the study was not performed double blindly, we question internal 
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validity in this study design. 
Hoffmann et al. 15 performed a prospective, randomized clinical trial in 80 ISSHL 
patients comparing the Ginkgo Biloba-extract EGb 76l (Tebonin®) to naftidrofuryl. 
EGb 761 has vasoregulative activity, platelet activating factor antagonizing properties 
and it prevents membrane damage by inhibition of free radicals. After two weeks a 
borderline benefit (p = 0.06) of EGb 761 in relative hearing gain was found. The 
hearing gain was comparable to the hearing gain found when no therapy is 
established. No placebo treated control group is included, and the study was not 
performed double blindly. In this study design, we question comparativeness and 
internal validity. 
Table 1: Treatment of iSSHL: Optimizing cochlear blood flow 
Clinical study 
Kronenberg et al. • 
Kubo et al.7 
Shirashi et al." 
Probst et at.• 
Wissen, Aziz 111 
Hagen" 
Wilkins et al. '2 
Koehn, Nickolu 
Laskawi et al. 1' 
Hoffman et al." 
Hultcranz et al.1• 
Bahgat, Shenoi 17 
Fisch'" 
Treatment 
procain/dextran vs placebo 
baxtrobin v. bethamethasone 
dextran/ pentoxifylline v. placebo 
dextran/ pentoxifillin v. 
dextran/ novocain/ nitotinic acid v. nicotinic acid/ novocain 
rt-PA 
histamine, dextran, diatriozate meglumine, carbogen, histamine, nicotic 
acid, diazide, dexamethazone. 
naftidrofuryl 
naftidrofuryl v. pentoxyfillin 
EGb 76 1 v. naftidrofuryl 
dextran, nicotinic acid, vitamin B 
02/ C02 inhalation 
02/ C02 inhalation v. papaverine/ dextran 
Hultcranz et al. 16 retrospectively evaluated the use of dextran, nicoumc acid and 
vitamin B in 80 ISSHL-patients. 32.5% of patients completely recovered, 35% 
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showed marked hearing improvement and 1 8.8 % moderate hearing improvement. 
Since no control group is included, establishing the therapy bound effect is 
impossible in this study. Treatment results approximate the spontaneous recovery rate 
in ISSHL. Based on this evaluation, the authors discontinued the use of this therapy 
modus in ISSHL. The study was not designed according to our criteria on 
comparativeness, internal and external validity. 
Baghat and Shenoi 17 reported treatment of four well-documented cases of ISSHL with 
inhalation of a 5% C02 I 95% 02 gas mixture, and found improvement of hearing in 
three cases. The study design did not fulfill our requirements concerning 
comparativeness, internal and external validity. Fisch18 used carbogen inhalation in 
sudden deafness. In a prospective randomized clinical trial 46 patients suffering 
sudden deafness were treated either with inhalation of 95% 02 and 5% C� or with 
intravenous papaverine hydrochloride and dextran. Five days after treatment, no 
significant difference in hearing improvement was found between both groups. The 
study design did not entirely fulfill our requirements on comparativeness, internal and 
external validity. 
B. Experimental studies (Table 2) 
Nagahara et al. 19 have measured perilymph oxygen levels in inner ear hearing losses 
of various etiology. In sudden hearing loss they found low initial values of perilymph 
oxygenation and a normal rise in perilymph oxygenation in response to carbogen 
inhalation. Normal values were deduced from values obtained in two otosclerotic 
patients and in cats. Hearing was not influenced by the restoration of normal 
perilymphathic oxygenation. 
Table 2: Treatment of ISSHL: Optimizing cochlear blood flow 
Experimental study 
Nagahara et al.'" 
Yagi et al. 111 
Pollock et al. 21 
Prazma et al.21 
Treatment 
02 I C02 inhalation 
Angiotensin, papaverine, furosemid, pyridylcarbinol, 
naftidrofuryl, dextran, histamine, glycerol. NaCO, 
02 1 C02 inhalation 
02 I C02 inhalation 
Yagi et al.20 measured oxygenation of perilymph in cats in response to injection of 
vasoactive drugs. Of all drugs tested, only angiotensin induced a significant rise in 
perilymphathic p02• Papaverine hydrochloride, furosemid, pyridylcarbinol, 
naftidrofuryl and low molecular dextran did not alter perilymphathic p02; histamine, 
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50% glycerol and 7% Na2C02 reduced perilymphathic p02• 
Pollock et al.21 demonstrated a rise in temporal bone blood flow in dogs, following 
inhalation of a C02 I 02 gas mixture. 
Prazma et al.22 demonstrated a rise in endocochlear 02, endocochlear potential and a 
slight decrease of cochlear microphonics in guinea pigs breathing a I 0% C02 I 90% 
02 gas mixture. 
II. Anti- inflammatOQ' medication (Table 3) 
In spite of their wide clinical use, few randomized prospective double blind clinical 
trials on the use of steroids in ISSHL are available. We encountered two studies in 
which the definition of ISSHL approximated our inclusion and exclusion criteria. 
Wilson et al.23 performed a double blind clinical trial including 67 ISSHL patients. 
Thirty-three received the steroids dexamethasone or methylprednisolone, 34 received 
a placebo. Fifty-two patients refused to participate and functioned as an untreated 
control group. After matching for age and vertigo, the steroid group achieved better 
hearing recovery than the placebo treated group and the untreated control group. This 
difference was significant (p = 0.0 17). Study design fulfilled our requirements 
concerning comparativeness, internal and external validity. The authors found viral 
infection of the cochlea most likely to cause of ISSHL and ascribe the beneficial 
effect of steroids to their anti-inflammatory action. However, patients presenting with 
a profound hearing loss remained refractory to therapy. 
Moskowitz, Lee and Smith24 performed a prospective clinical trial in 36 patients 
suffering ISSHL. Twenty-seven received dexamethazone, 9 received a placebo. Of 
the dexamethazone treated group, 89% recovered to functional hearing levels. Of the 
placebo group 44% recovered. This difference was statistically significant (p < 0.0 1 ) . 
Study design fulfilled our requirements concerning comparativeness. The study was 
designed as a randomized prospective clinical trial, but double blinding is lacking, 
and therefore our requirements on internal validity are not entirely met. 
Table 3: Treatment of ISSHL: Anti-inflammatory medication 
Clinical study Treatment 
Wilson et a!." dexamethazone/ methylprednisolone v. placebo 
v. untreated. 
Moskowitz et al.24 dexamethazone v. placebo 
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ill. Miscellaneous treatment (Table 4) 
Numerous reports on various treatment strategies in ISSHL are available, including 
stellate ganglion block 25•26 , multistep oxygen therapy 27, hyperbaric oxygen therapy 28, 
natrium-meglumine-diatrizoate (Urografin®)29 , diatrizoate meglumine (Hypaque ® ) 30 
and xantinolnicotinate (Complamine '-' ) 31 , but no randomized double blind clinical 
trials are available to ascertain the therapeutic values of most of these strategies. 
A few studies approximating our demands of comparativeness, internal and external 
validity are listed in table 4. 
Use of the calcium antagonist nimodipin (Nimotop®) has been evaluated by Lenari2 • 
The primary therapeutic effect of calcium antagonists is the result of a vasodilatory 
and spasmolytic action on cerebral vessels. Secondly, a protective effect on hypoxic 
sensory cells is supposed, due to their property to lower intracellular calcium, thus 
lowering ATP use in these damaged cells. Eighty ISSHL patients were randomly 
assigned to two groups (n = 40), the first group receiving naftidrofluryl only, the 
second group also receiving nimodipine. No statistically significant difference 
between both groups was found. The definition of ISSHL used in this study did not 
entirely fulfill our inclusion and exclusion criteria. Although our demands on 
comparativeness, randomization and prospectiveness were met, double blinding is 
lacking, and therefore internal validity is questionable. 
Meier et al.33 evaluated treatment effectiveness of the calcium antagonist flunarizine 
(Sibelium®) in ISSHL in a non-randomized non-double blind prospective clinical 
trial. Thirty-seven patients received flunarizine, 67 placebo treated patients of a 
previous study9 functioned as a control group. It was concluded that flunarizine did 
not improve recovery of sudden hearing loss. In this design, we question 
comparativeness, internal and external validity. 
Table 4: Treatment of ISSHL: Miscellaneous treatment 
Clinical study Treatment 
Lenarz32 nimodipin +/· naftidrotluryl 
Meier et at." flunazerine v. placebo 
Michel and Matthias34 taprosten v. mannitol 
Michel and Matthias34 performed a placebo-controlled double blind study on the 
treatment of ISSHL with the stable prostacyclin analog taprosten, assumed to have 
both vasodilatory and thrombocyte aggregation inhibiting properties. Twenty-two 
ISSHL patients were randomly assigned to taprosten or placebo treatment. Low-dose 
mannitol functioned as placebo. No statistically significant difference could be found 
28 
between both groups. The choice of placebo weakens comparativeness, internal and 
external validity in this study. 
Discussion and conclusions 
In ISSHL, therapy based on improving cochlear blood supply has been used 
extensively, although the use of plasma expanders and vasodilators lacks both 
experimental and clinical support. A beneficial effect of defibrinogenase therapy 
cannot be established, and a "shotgun" therapy for ISSHL only causes adverse effects. 
Studies on the use of naftidrofuryl lack proper design and thorough evaluation. 
Inhalation of C0/02 , although well evaluated experimentally, has not proven to be 
of clinical use. 
In the literature, we found two well-designed studies supporting the beneficial effect 
of steroids in achieving hearing recovery in ISSHL, although the level to which 
hearing recovery is achieved is disappointing. 
Reports on miscellaneous treatment modalities are numerous. Only a few studies 
meet our requirements concerning study design. In three well-designed studies the 
effect of two calcium antagonists and a prostracyclin analog was evaluated. No 
beneficial effect on achieving hearing improvement could be demonstrated. 
In conclusion, no truly successful treatment modality in ISSHL exists. Application of 
steroids has a modest beneficial effect on hearing recovery. 
In an extensive review of the literature, the etiology of ISSHL according to  our 
definition is critically judged on clinical and experimental evidence4• A viral 
labyrinthine infection is regarded to be responsible for a large proportion of ISSHL. 
The beneficial effect of steroid therapy can be explained by its anti-inflammatory 
action, as described in earlier reports. 
A viral pathogenesis of ISSHL deserves further attention in experimental reo;earch 
and therapy. Therefore, we recommend ISSHL treatment to take place within a 
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Chapter 4 
DIAGNOSIS AND TREATMENT 
OF IDIOPATIDC SUDDEN SENSORINEURAL HEARING LOSS: 
a survey in the Netherlands and Flanders 
Stokroos RJ, Albers FWJ. Idiopathic Sudden Sensorineural Hearing Loss, diagnose 
en behandeling door 229 Nederlandse keel-, neus- en oorartsen. Resultaten van een 
nationale enquete. Nederlands tijdschrift voor keel-, neus- en oorheelkunde 1 995; 4: 
1 3 1 -7 .  
Stokroos RJ, Albers FWJ, Van Cauwenberge P.  Diagnosis and treatment of 
Idiopathic Sudden Sensorineural Hearing Loss (ISSHL): a survey in the Netherlands 
and Flanders. Acta ORL Belg 1996; 50: 237-45. 
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Introduction 
Diagnosis and treatment of Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) 
remain controversial entities in otology. When ISSHL is diagnosed "per exclusio­
nem", discussion arises about its definition and the applied clinical analysis. Choice 
of treatment is perhaps even more contradictory. 
We report the extent of (dis)agreement on diagnosis and treatment of ISSHL within 
the Dutch language region. We questioned all ENT-surgeons practising in the 
Netherlands and in Flanders (Dutch speaking part of Belgium) on definition, 
diagnosis, possible etiology, therapy and treatment results in ISSHL. We recommend 
a more rational approach to diagnosing and treating ISSHL. 
Methods 
A questionnaire containing 1 0  multiple-choice questions was designed. The questions 
concerned definition, incidence, diagnosis, treatment and follow-up of ISSHL. 
Respondents were also asked to judge several etiological hypotheses, and to estimate 
their treatment results. The questionnaire was validated by the Office for Medical 
Technology Assessment of the University Hospital Groningen. All 373 ENT-surge­
ons practising in the Netherlands and all 2 1 5  ENT -surgeons practising in Flanders 
received the questionnaire. Data were processed anonymously on an IBM compatible 
personal computer, using dBASE V (Borland International) and QuattroPro I 
(Borland International). Statistical analysis was performed using SPSS VI (SPSS 
inc.). 
Response 
In the Netherlands, 373 ENT-surgeons received our questionnaire. 240 forms were 
returned of which 10 forms were not filled in properly. 230 forms were included in 
this study (62%). In Flanders, 2 1 5  ENT-surgeons received our questionnaire. 5 1  
forms were returned of which 1 form was not filled in properly. 50 forms were 
included in this study (23%). In total, we report the opinion of 280 ENT-surgeons 
(48%) practising in the Dutch language region, containing approximately 2 1 .5 million 
inhabitants. 
Results 
Definition of ISSHL: Diagnostic qriteria (Table 1 )  
"Hearing loss of unknown origin" was used as a diagnostic criterion by 83% of the 
Dutch ENT -surgeons and by 69% of the Flemish ENT -surgeons. The sensorineural 
nature of the hearing loss was considered a diagnostic criterion by 74% ot the Dutch 
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and 76% of the Flemish respondents. The suddenness of hearing loss was important 
to 72% of the respondents in the Netherlands and to 54% of the respondents in 
Flanders. Hearing loss occurring within at most 24 hours was generally considered 
"sudden" .  For 57% of the Dutch respondents and 40% of the Flemish respondents, 
the severity of the hearing loss should average at least 30 dB. The extent of hearing 
loss, indicated by the number of frequency steps in the standard pure-tone audiogram 
involved in hearing loss, was a diagnostic criterion for 47% of the Dutch, and 42% of 
the Flemish respondents. Hearing loss occurring in 3 out of 7 steps in frequency ( 125 
Hz, 250 Hz, 500 Hz, 1 000 Hz, 2000 Hz, 4000 Hz, 8000 Hz) was required minimally 
to diagnose ISSHL. 
Exclusion criteria were used by both the Dutch and the Flemish ENT-surgeons in 
diagnosing ISSHL. A recent trauma capitis (69% v. 60%) or a recent barotrauma 
(67% v. 58%) was frequently mentioned as exclusion criterion. A compromised 
otological history (42% v. 30%) or the recent use of potentially ototoxic medication 
(55% v. 34%) was used less often as an exclusion criterion for diagnosing ISSHL. 
Definition of ISSHL, by application of diagnostic criteria, differed between the two 
groups of respondents. A statistically significant difference in opinion existed 
between the Dutch and Flemish ENT -surgeons regarding the unknown origin, the 
suddenness and the severity of the hearing loss, and to the recent use of potentially 
ototoxic medication. (p !> 0.05, Chi-square test) 
Table 1: Definition of iSSHL: diagnostic criteria. 
Diagnostic criteria in ISSHL NL F 
n=230 n=50 
hearing loss of unknown origin* 83% 69% 
sensorineural hearing loss 76% 74% 
sudden hearing loss* 72% 54% 
hearing loss averages at least 30 dB* 57% 40% 
no. of audiogram frequencies in which hearing loss occurs 47% 42% 
absence of recent trauma capitis 69% 60% 
absence of recent barotrauma 67% 58% 
compromised otological history 42% 30% 
recent use of potentially ototoxic medication* 56% 34% 
* difference statistically significant (p s 0.05, Chi-square test) 
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Incidence of JSSHL 
In the Netherlands, 228 of 229 respondents (99.6%) diagnosed ISSHL. In Flanders, 
all 50 respondents diagnosed ISSHL. On average, the individual ENT-surgeon 
diagnosed ISSHL 3.0 (range 0. 1 - 40) times annually in the Netherlands and 4.4 
(range 1 - 20) times annually in Flanders. 
Diagnosis of ISSHL (Table 2a-e) 
a. Clinical examination 
In cases of sudden hearing loss, otoscopy was performed by 99.6% of the Dutch and 
by all of the Flemish ENT-surgeons, inspection of the nasopharynx by 49% v. 62%, 
rhinoscopia anterior by 4 1 %  v. 52%, inspection of the oropharynx by 37% v. 50%, 
palpation of the neck by 37% v. 30% and indirect laryngoscopy by 27% v. 26%. A 
general physical examination was performed by 1 6% of the Dutch and 1 8% of the 
Flemish ENT -surgeons. The extent of clinical evaluation was comparable between 
both groups. (p !':: 0.05, Chi-square test) 
Table 2a: Diagnosis of ISSHL: clinical e11amination. 
Clinical examination in ISSHL NL F 
n=230 n=50 
otoscopy* 99,6% 1 00% 
inspection of nasopharyn11* 49% 62% 
rhinoscopia anterior* 4 1 %  52% 
inspection of oropharyn11* 37% 50% 
palpation of the neck* 37% 30% 
indirect laryngoscopy* 27% 26% 
general physical e11amination* 1 6% 1 8% 
* differences not statistically significant (p > 0.05, Chi-square test) 
b. Audiovestibular evaluation 
Pure-tone audiometry was performed by 96.6% of the Dutch and 98% of the Flemish 
respondents. Speech audiometry was performed by 84% of the Dutch and 34% of the 
Flemish respondents. Tuning fork tests according to Weber and Rinne were used 
frequently (82% v. 80%) by both groups. Impedance measurements were performed 
by 69% of the Dutch and 80% of the Flemish respondents. Stapedial reflex analysis 
was performed by 5 1 %  and 76%, Brainstem Evoked Response Audiometry (BERA) 
was performed by 64% and 82% of the Dutch and Flemish respondents respectively. 
Evaluation of nystagmus using glasses according to Frenzel was done by 34% of the 
Dutch and 54% of the Flemish ENT-surgeons. Electronystagmography evaluation 
36 
using caloric provocation was done by 46% of the Dutch and 68% of the Flemish 
respondents. Rotational chair provocated electronystagmography was performed by 
17% of the Dutch respondents and by 54% of the Flemish respondents. 
The extent of the audiovestibular evaluation in ISSHL differed between both 
countries. A statistically significant difference was found in the application of speech 
audiometry, stapedial reflex measurement, BERA, the use of glasses according to 
Frenzel and electronystagmography. (p � 0.05, Chi-square test) 
Table 2b: Diagnosis of ISSHL: audiovestibular evaluation. 
Audiometric evaluation in ISSHL NL F 
n=230 n=50 
pure-tone audiometry 96,6% 98% 
speech audiometry* 84% 34% 
tuning fork testing 82% 80% 
impedance measurements 69% 80% 
stapedial reflex evaluation* 5 1 %  76% 
Brainstem Evoked Response Audiometry (BERA)* 64% 82% 
glasses according to Frenzel*  34% 54% 
electronystagmography with caloric provocation* 46% 68% 
electronystagmography with rotational chair provocation* 17% 54% 
* difference statistically significant ( p � 0.05, Chi-square test) 
c. Laboratory investigations 
Full blood cell count and differentiation (78% v. 82%), erythrocyte sedimentation 
rate (68% v. 44%), and serum electrolytes (52% v. 72%) were the laboratory 
investigations most often performed in ISSHL patients in the Netherlands and in 
Flanders. Paired virus serology (38% v. 64%) and VDRL (41 %  v. 54%) were also 
frequently determined in both the Netherlands and Flanders. Evaluation of the 
haemostatic pathway ( 1 5% v. 30%), immunoglobulin levels ( 1 6% v. 38%), 
Monosticon test (8% v. 6%) Paul Bunnell test ( 1 1% v. 26%), Wasserman (32% v. 
1 8%), Anti Nuclear Cytoplasmatic Antigens (ANCA), Anti Nucleic Antigen (ANA), 
Anti double string DNA ( 15% v. 40%), Mycoplasma pneumoniae serology (3% v. 
6%) and Borrelia burgdorferi serology (20% v. 26%) took place less often. 
The extent of laboratory evaluation differed considerably between the Netherlands 
and Flanders. Only full blood cell count and differentiation, VDRL, Monosticon, 
Mycoplasma pneumoniae and Borrelia burgdorferi serology were performed equally 
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often. All other laboratory investigations differed significantly in frequency. (Chi­
square test, p � 0.05) 
Table 2c: Diagnosis of ISSHL: laboratory evaluation 
Laboratory evaluation in ISSHL NL F 
n=230 n=50 
full blood count and differentiation 78% 82% 
erythrocyte sedimentation rate* 67% 44% 
serum electrolytes* 52% 72% 
paired virus serology* 38% 64% 
VORL 4 1 %  54% 
Wasserman* 32% 1 8% 
haemostatic pathway* 15% 30% 
immunoglobulins* 16% 38% 
Monosticon 8% 6% 
Paul Bunnell* I I % 26% 
ANCA, ANA, Anti ds-DNA* 15% 40% 
Mycoplasma Pneumoniae serology 3% 6% 
Borrelia Burgdorferi serology 20% 26% 
* difference statistically significant (p ,; 0.05, Chi-square test) 
d. Imaging techniques 
Computed tomography of temporal bones and skull base was frequently performed in 
ISSHL in the Netherlands (54%) and in Flanders (62%). Magnetic resonance imaging 
of temporal bones and skull base was also used frequently in the Netherlands ( 44%) 
and in Flanders (52%). X-ray projections according to SchUller and Stenvers were 
seldom used in the Netherlands ( 13% respectively I I %) and in Flanders (4% 
respectively 2%). A standard thoracic X-ray was rarely made in ISSHL (4% v. 8%). 
The use of scanning techniques was comparable in both countries. Conventional 
projection techniques were performed significantly less often in Flanders (p � 0.05, 
Chi-square test). 
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Table 2d: Diagnosis of ISSHL: imaging techniques. 
Imaging in ISSHL NL F 
n=230 n=50 
CT -scan temporal bones and skull base 54% 62% 
MRI temporal bones and skull base 44% 52% 
X Schiiller* 1 3% 4% 
X Stenvers* I I % 2% 
X Thorax 4% 8% 
* difference statistically significant (p s 0.05, Chi-square test) 
e. Consultation of other specialties 
Neurologist (40%) and internist (34%) were frequently consulted in the Netherlands, 
and in Flanders (46% and 28%). Consultation of ophthalmologist (8% v. 1 2%) and 
immunologist (7% v. 8%) occurred less frequently. No statistically significant 
differences were found between both countries. (p :;; 0.05; Chi-square test) 
Table 2e: Diagnosis of ISSHL: consultation of other specialities 






* differences not statistically significant (p > 0.05, Chi-square test) 






8% 1 2% 
7% 8% 
1 %  6% 
The interval between occurrence of ISSHL and initiation of treatment appears to be of 
prognostic significance1 • This was important to 77% of the Dutch and 68% of the 
Flemish ENT-surgeons. In the Netherlands, 12 (range 1 -3 1 )  days after the occurrence 
of hearing loss, treatment was generally considered to be fruitless; in Flanders, this 
was 20 (range 3-60) days after hearing loss occurred. 
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b. Therapy 
In the Netherlands, ENT-surgeons frequently prescribed corticosteroids in ISSHL 
(63%). Rest was often advised (53%). In Flanders, corticosteroids were prescribed by 
84% and rest was advised by 32% of the responding ENT-surgeons. Vasodilators 
(37% v. 78%), plasma-expanders (24% v. 26%) and anticoagulants ( 1 7% v. 22% ) 
were used less frequently in ISSHL in both the Netherlands and in Flanders. An­
ti-histamines ( 16% v. 6%), Calcium-entry-blockers (9% v. 1 0%), C02 inhalation (5% 
v. 22%) and contrast dyes ( 1 %  v. 0%) were rarely applied in ISSHL in both countries. 
Eight percent of the Dutch respondents did not treat ISSHL at all. 
Steroids, vasodilators and C02 inhalation are prescribed more often in Flanders. In 
the Netherlands, rest is advised more frequently and the decision not to treat ISSHL is 
more common. (p s 0.05, Chi-square test) Other treatment modalities are used to a 
comparable extent in the Netherlands and Flanders. 
Table 3a: Treatment of ISSHL 
Treatment of ISSHL NL F 
n=230 n=50 
corticosteroids• 63% 84% 
(bed)rest* 53% 32% 
vasodilators* 37% 78% 
plasma-expanders 24% 26% 
anticoagulants 1 7% 22% 
anti-histamines 1 6% 6% 
Calcium-entry blockers 9% 10% 
CO, inhalation* 5% 22% 
contrast dyes 1 %  0% 
no treatment* 8% 0% 
• difference statistically significant ( p � 0.05, Chi-square test) 
c. Clinical and ambulant treatment 
In the Netherlands, 52% of the ENT-surgeons considered hospital admission 
necessary for treatment of ISSHL. Seventy-six percent of their Flemish colleagues 
admitted ISSHL patients. Hospital stay averaged 7 days in the Netherlands and 5 days 
in Flanders. An outpatient follow-up was performed by 97% of Dutch and 98% of 
Flemish respondents. The duration of follow-up varied between 6 and 12 months in 
both countries. 
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d. Treatment results 
Thirty-four percent of the Dutch ENT-surgeons and 1 8% of the Flemish ENT­
surgeons estimated their therapy to result in usable hearing in 0 - 25% of their ISSHL 
cases. Thirty-five percent of the Dutch, versus 46% of the Flemish respondents 
estimated achieving usable hearing in 25 - 50% of their ISSHL cases. Seventeen 
percent of the Dutch, versus 28% of the Flemish respondents estimated to achieve 
this result in 50 - 75% of their ISSHL cases. One respondent claimed success in 
treating each ISSHL case. Both groups were comparable in estimating hearing 
recovery, although the Flemish ENT-surgeons were less pessimistic in estimating 
usable hearing in 0-25% of their cases. (p � 0.05, Chi-square test) 
Table 3b: Estimated treatment results in ISSHL 
Treatment results in ISSHL NL F 
n=230 n=50 
usable hearing in 0 - 25% of cases* 34% 1 8% 
usable hearing in 25 - 50% of cases 35% 46% 
usable hearing in 50 - 75% of cases 17% 28% 
usable hearing in 75% -I 00% of cases 1% 0% 
* difference statistically significant. ( p s 0.05. Chi-square test) 
Conceptions about the etiology of /SSHL (Table 4) 
A disturbance of labyrinthine blood circulation (7 1 %  v. 66%) and viral labyrinthine 
infection (55% v. 70%) were most often postulated as a cause for ISSHL in the 
Netherlands and in Flanders. Thirty percent versus 32% of respondents suggested 
ISSHL to be the result of an underlying autoimmune disease. An acute hydrops of the 
labyrinth was thought to be the cause of ISSHL by 14% of the respondents in both 
countries. Thirteen percent versus 16% assumed labyrinthine membrane ruptures to 
cause ISSHL. A viral etiology is significantly preferred in Flanders (p s 0.05, Chi­
square test). The other hypotheses are supported to the same extent in both countries. 
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Table 4: Conceptions about the etiology of ISSHL 
Supposed etiology of ISSHL NL F 
n=230 n=50 
disturbance of labyrinthine blood circulation 7 1  o/o 66% 
viral labyrinthine infection* 55% 70% 
underlying autoimmune disease 30% 32% 
acute labyrinthine hydrops 14% 14% 
labyrinthine membrane rupture 1 3% 1 6% 
* difference statistically significant ( p s 0.05, Chi-square analysis) 
Discussion 
On average, Idiopathic Sudden Sensorineural Hearing Loss is diagnosed 3.0 times 
annually by the Dutch ENT-surgeon. His Belgian colleague makes this diagnosis 4.4 
times annually. In the Netherlands an incidence of 8 new cases of ISSHL per 100,000 
inhabitants can be estimated. An incidence of 14.6 new cases per 100,000 inhabitants 
can be estimated in the Dutch speaking part of Belgium. These numbers are 
comparable to the incidence of ISSHL reported in the USA ( I  0. 7 new patients per 
1 00,000 inhabitants per annum1) and to the incidence of ISSHL reported in Japan 
( 1 3.7 new patients per 1 00,000 inhabitants2) .  
The sudden occurrence of sensorineural hearing loss of enigmatic etiology is a 
diagnostic criterion for the majority of respondents. On average, hearing loss must 
occur within 24 hours to be considered 'sudden'.  The severity of the hearing loss is 
also frequently considered to be a diagnostic criterion, its severity being at least 30 
dB, its extent averaging at least 3 of 7 one octave steps in frequency. Exclusion of 
events possibly related to hearing loss is regarded as important. Otological and 
medication history are less important for establishing the diagnosis of ISSHL. 
Flemish ENT surgeons use less stringent diagnostic criteria when diagnosing ISSHL. 
ISSHL is diagnosed more often in Flanders when compared to the Netherlands. 
Systematic application of in- and exclusion criteria in sudden hearing loss, therefore, 
seems to lead to a reduction in the number of cases considered to be idiopathic. 
ISSHL is a diagnosis per exclusionem. Therefore, in our opinion, a careful evaluation 
is of paramount importance for each patient suspected of sudden hearing loss in order 
to prevent diagnostic omissions. 
We found considerable shortcomings in the thoroughness of ISSHL evaluation. In a 
majority of ISSHL cases a complete ENT-examination is not performed and 
laboratory evaluation is incomplete. Audiological evaluation is performed thorough 
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in the Netherlands, but speech audiometry, estimating functional hearing, is 
performed by a minority of ENT-surgeons in Flanders. Vestibular evaluation is more 
thorough in Flanders, thus elucidating an early prognostic factor. Although modem 
imaging techniques are applied in ISSHL, this evaluation is lacking in a significant 
proportion of ISSHL patients, thereby underestimating retrocochlear and systemic 
causes of sudden hearing loss. Disagreement on diagnostic procedures in ISSHL 
between individual ENT-surgeons is reflected by the large differences found between 
Dutch and Flemish ENT-surgeons. The estimation of legal consequences and the 
method of health care financing differs between both countries and might vary 
between individual ENT-surgeons. 
When treating ISSHL, a time interval is often used after which treatment of ISSHL is 
considered to be fruitless. Corticosteroids are frequently prescribed as the only 
treatment modality that has proven to be beneficial in ISSHL 3.4·5 • Treatment is often 
accompanied by advising the patient to rest. This advice probably has a more intuitive 
than scientific foundation. In a majority of cases, treatment modalities of ISSHL lack 
scientific foundation and can be considered to be potentially harmful 5'9• While in the 
Netherlands monotherapy is often advocated in ISSHL, in Flanders a combination of 
various treatment modalities is used more often. A combination of treatment 
modalities in ISSHL does not possess significant advantages9• The treatment results 
as estimated by the responding ENT-surgeons are comparable to the spontaneous 
recovery rate of ISSHL, reported in the literature to occur in 45-65% of cases l . 10• 1 1 • 
Viral labyrinthine infection and disturbance of cochlear blood flow are two 
hypotheses frequently mentioned in the literature as causes of ISSHL1 1 • Our 
respondents also frequently mentioned these hypotheses as possible causes of ISSHL. 
Recommendations 
We find it desirable to define ISSHL more precisely, thereby limiting ISSHL to the 
truly idiopathic cases. This can be implemented by the use of a diagnostic protocol 
based on a differential diagnosis, thereby preventing diagnostic omissions. 
Fundamental research aimed at elucidating the etiology of ISSHL might lead to 
further agreement on diagnostic and therapeutic procedures. Treatment results have 
been quite disappointing to this date. We therefore recommend treating ISSHL 
patients within a carefully designed clinical trial. 
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Chapter 5 
THE ETIOLOGY OF IDIOPATHIC SUDDEN SENSORINEURAL HEARING LOSS: 
experimental herpes simplex virus infection of the inner ear 
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The enigmatic pathophysiology of Idiopathic Sudden Sensorineural Hearing Loss 
(ISSHL) has elicited divergent hypotheses on its etiology. 
A disturbance of labyrinthine blood circulation provoking ISSHL has been postulated 
because its abrupt onset resembles other infarctions of the central nervous system. 
However, the wide age distribution and the average cardiovascular risk as observed 
among ISSHL patients is not in accordance to this hypothesis 14• Experimentally 
induced hearing loss of vascular origin is irreversible due to extensive cochlear 
fibrosis and ossification5•7 • These were not found in ISSHL in both post mortem 
temporal bone histopathological exarnination8· and in inner ear imaging studies 9 • 
Hearing recovers spontaneously in 45-65% of ISSHL-patients10· ' ' . Therefore, it is not 
entirely satisfactory to assume a labyrinthine blood circulation disturbance to be 
responsible for a large proportion of ISSHL-cases. 
A rupture of inner ear membranes might explain both the suddenness and the 
spontaneous recovery found in ISSHL, but clinical evidence is limited1w. Although a 
severe hearing loss can be provoked experimentally by inducing a double labyrinthine 
membrane rupture14, temporal bone histopathology of ISSHL patients does not 
provide evidence of (previous) membrane breaks8• Therefore, this hypothesis lacks 
convincing clinical and histopathological evidence too. 
Several systemic viral infections are able to provoke sudden hearing loss. The 
observation of viral upper respiratory infection often preceding ISSHL led to the 
supposition of viral cochlear labyrinthitis to cause ISSHL1�. Reports of 
seroconversion of herpes antibody titers in ISSHL16• 17 and the presence of latent 
neurotropic herpes viruses in the spiral ganglia of asymptomatic individuals 18, has 
drawn attention to the role of the herpes virus family in causing ISSHL. Further 
support for a viral etiology of ISSHL can be deduced from detailed descriptions of 
post mortem temporal bone histopathology of individuals with ISSHL who deceased 
of unrelated causes and from post mortem temporal bone histopathology of patients 
having suffered from viral labyrinthitis. The histopathological changes a� observed in 
the temporal bones of ISSHL patients showed resemblance to the temporal bone 
pathology of patients with viral labyrinthitis8• 19'22• Histopathology in ISSHL as 
described in the literature is summarized in table I .  
Schuknecht et al.8•19·20 described post mortem temporal bone histopathology of twelve 
cases of ISSHL. Light microscopic studies of the inner ear showed a variable degree 
of atrophy of the organ of Corti in 6 cases, a combination of pathological changes in 
the tectorial membrane and atrophy of the organ of Corti in 2 cases and pathological 
changes in the tectorial membrane only in 2 cases. In 7 of 1 2  cases, a variable degree 
of atrophy was seen in the stria vascularis. Loss of cochlear neural population was 
present in 3 cases. No cochlear pathology was found in the one case in which hearing 
returned to normal before decease. Yoon et al?1 reported post mortem temporal bone 
histopathology in 5 cases of ISSHL. Atrophy of the organ of Corti, pathological 
changes of the tectorial membrane, atrophy of the stria vascularis and loss of cochlear 
neurons and nerve fibres were found. Sando et al.a reported light microscopic 
46 
findings in 2 patients having suffered from ISSHL and found atrophy of the organ of 
Corti in combination with atrophy of the tectorial membrane and the stria vascularis 
and a decrease in the number of cochlear nerves. 
Table 1 :  Cochlear histopathology in Idiopathic Sudden Sensorineural Hearing Loss 
Schuknecht"·'•.z• YoonZI Sando12 
Perilympathic 
Scala tympani 0 0 0 
Scala vestibuli ? ? ? 
EndolymphathiC 
Stria vascularis + + + 
Reissner's membrane 0 0 0 
Basilar membrane 0 0 0 
Sensory end-organ 
Organ of Corti + + + 
Tectorial membrane + + + 
Neural structures 
Ganglion cells + + + 
Nerve fibres + + + 
(+: damaged, 0: normal, ?: unknown) 
In a description of human post mortem temporal bone histopathology in Ramsay 
Hunt syndrome by Blackley et al.23, perineural and intraneural lymphocytic 
infiltrations were observed in cochlear structures. The stria vascularis appeared 
atrophied, the organ of Corti was partially degenerated and covered by a collapsed 
Reissner's membrane. Zajtchuk et al.24 described cochlear histopathology in Ramsay 
Hunt syndrome in which hearing had returned to normal before decease. On light 
microscopy, except for a slight detachment of the tectorial membrane, no cochlear 
abnormalities were found. 
The key to successful treatment of any pathological condition lies in the 
understanding of its pathophysiology. In ISSHL, the delicacy of the structures 
involved obliges us to develop a model to study its pathophysiology. Based on the 
earlier summarized evidence, the herpes virus family might play an etiological role in 
provoking ISSHL by causing a subclinical viral labyrinthitis. The development of an 
animal model in which herpes induced viral labyrinthitis can be studied, might help 
us to solve some of the enigmas surrounding ISSHL. 
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Material and methods 
Thirteen healthy male albino guinea pigs (weight 400-500 g.) with a positive Preyer 
reflex received Halothane* general anaesthesia. Via a retroauricular incision, the 
tympanic bulla of the left ear was exposed and opened. A bevelled glass pipette 
(World Precision Instruments), with a tip measuring 50 micrometres in diameter was 
introduced through the round window membrane into the perilymphatic space, using 
a micromanipulator (World Precision Instruments). Via a microdosage system 
(Mitutoya), two microlitres of a herpes simplex virus type 1 (HSV - 1 )  suspension 
were injected in two minutes into the perilymphatic space. HSV- 1 ,  Mcintyre strain, 
was grown in monolayers of human embryonic lung fibroblasts, using culture 
medium consisting of minimal essential medium and Hanks' salts supplemented with 
fetal calf serum. When the fibroblasts showed an extensive cytopathic effect, the 
culture supernatant was cleared by centrifugation at 2000 r.p.m. for 1 0  minutes. This 
cleared supernatant, which contained 8 x 104 TCIDso units per microlitre, was used 
for infecting the guinea pigs. 
Two groups were formed: 4 animals received the culture medium only and functioned 
as a control group, 9 animals were inoculated with the virus suspension. Each day, 
auditory function monitoring using the Preyer reflex25 and vestibular function 
monitoring using the head tilt reflex was performed. Blood samples were obtained 
both prior to inoculation and just before sacrifice and HSV antibody titers were 
determined in both samples in the following two different ways. Complement fixing 
HSV antibodies were measured by a modification of the Laboratory Branch 
Complement Fixation micromethod26, which can also be applied on sera from guinea 
pigsn. HSV -specific IgG titres were determined by indirect immunofluorescence on 
acetone fixed HSV-infected cells, using fluorescein isothiocyanate-labeled goat anti­
guinea pig IgG reagent (Soutern Biotechnology Associates Inc.). On day seven, all 
animals were sacrificed. Primary fixation was performed by intralabyrinthine 
perfusion with 2.5% glutaraldehyde in a 0.08 mol/L sodium cacodylate buffer (pH 
=7.4). After dissection of the cochlea, immersion fixation with the same fixative was 
carried out during three hours. Decalcification took place in 10% EDTA-2Na (pH= 
7.4). Postfixation was performed using 1 %  Os04 and 1 .5 %  K4 Ru(Cn)6 followed by 
dehydration in graded alcohol. After embedding, midmodiolar sections of the cochlea 
were stained toluidine blue and evaluated using light microscopy (Olympus OM2) 
and transmission electron microscopy (Philips EM201 ,  60 kV) by a panel of four 
independent observers experienced in the evaluation of inner ear pathology. 
Results 
Audiovestibular function 
Animals inoculated with the culture medium only showed no sign of hearing loss or 
vestibular dysfunction. All the animals inoculated with HSV - 1  showed ' an absent 
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Preyer reflex in the inoculated ear, indicating hearing loss. Hearing did not recover. 
No vestibular dysfunction was observed in these animals during the experimental 
period. 
Serology 
No systemic symptoms of herpes infection were observed in any of the animals. 
However, HSV-IgG seroconversions were demonstrated in all HSV inoculated 
animals and in none of the control animals. HSV-IgG titers in the second serum 
samples, of the infected animals, as measured by immunofluorescence, varied 
between 10 and � 80 (median titer 20). No HSV antibodies were found when the less 
sensitive complement fixation test was used. 
Light Microscopy (Table 2) 
In the animals which were inoculated with the culture medium only, no structural or 
morphological changes were observed in the cochlea. In all animals inoculated with 
HSV - 1 ,  we found some blood cells in the scala vestibuli. In the scala tympani, these 
blood cells were embedded in a loose peripheral network of fibrosis, but a large 
central lumen remained. In the scala media, no blood cells or fibrosis were observed. 
Reissner's membrane had a normal appearance in most animals. 
Table 2: Cochlear histopathology in experimental herpes simplex type I viral labyrinthitis 
HSV-1 Culture medium 
Perilympatlc 
Scala tympani 01+ 0 
Scala vestibuli ++ 
Endolymphatic 
Stria vascularis ++I+++ 
Reissner's membrane 0 0 
Basilar membrane 0 
Sensory end-organ 
Organ of Corti ++I+++ 0 
Tectorial membrane +I++ 
Neural structures 
Ganglion cells + 0 
Nerve fibres ++ 
(+++ = destroyed, ++ = damaged, + =  slight damage, 0 = normal) 
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The stria vascularis showed a disturbed architecture (fig. 1 ) :  in the intermediate cell 
layer, blood vessels showed an increased diameter and were filled with erythrocytes. 
The stria vascularis had a swollen appearance with the presence of increased 
intercellular spaces in the intermediate cell layer. Extensive histopathological changes 
were observed in the organ of Corti. The supporting cells (inner and outer pillar cells, 
inner and outer phalangeal cells) were very difficult to recognize due to 
morphological changes. The sensory cells were frequently replaced by the supporting 
cells. Outer and inner hair cells had disappeared completely in the basal windings, but 
in two animals, they could be recognized with difficulty in the apical coils. The 
tunnel of Corti was not recognizable. The tectorial membrane showed an increased 
distance from the organ of Corti, but its shape remained unchanged (fig. 2). Ganglion 
cells and neural structures showed a lymphocellular infiltration. 
Figure 1: Light microscopy of the stria vascularis in experimental HSV I labyrinthitis (250x). Dilated 
vessels and erythrocyte sludging (arrow). Swollen appearance and increased intercellular spaces in the 
intermediate cell layer (asterisk). 
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Figure 2: Light microscopy of the organ of Corti in experimental HSV - 1  labyrinthitis (250x). 
Extensive destruction of the organ of Corti and supporting cells. The tectorial membrane is disrupted 
from the sensory cells, but has a normal appearance (arrow). 
Transmission Electron Microscopy 
Reissner' s membrane appeared thickened on light microscopic evaluation in some of 
our animals. Transmis�ion electron microscopy (TEM) showed an intact basement 
membrane between the thin mesothelial cell layer and the epithelial cell layer. The 
epithelial cells possessed a multilobulated, ovoid nucleus and a well-developed Golgi 
complex. Its cell junctions were normal (fig. 3). 
The tectorial membrane is observed to elevate or loosen from the organ of Corti and 
from the limbus spiralis in many cases of HSV-1 viral labyrinthitis. TEM evaluation 
showed a disturbed relation between interdental cells and the tectorial membrane 
(fig. 4). 
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Figure 3: Transmission electron microscopy of Reissner's membrane in experimental HSV - I  
labyrinthitis ( 1 5000x), showing cell junctions between epithelial cells: zonula occludens (ZO), 
fol lowed by zonula adhaerens (ZA) and desmosomes (D). 
Figure 4: Transmission electron microscopy of the tectorial membrane in experimental HSV - I  
labyrinthitis (4500x). Elevation of the tectorial membrane (asterisk) from the l imbus spiral is might be 




Experimentally induced HSV-1 labyrinthitis, causing both hearing Joss and gross 
structural damage to the cochlea, followed an otherwise symptomless course which 
was not accompanied by the appearance of HSV specific complement fixing 
antibodies. However, primary HSV infection could be confirmed by HSV-IgG 
seroconversion. Whether a non-primary local HSV infection, as might be present in 
ISSHL, can also be detected by HSV-IgG serology remains to be demonstrated. 
Experimental viral labyrinthitis has been induced by different inoculation routes, 
including inoculation along intralabyrinthine, middle ear, intracerebral, 
intraperitoneal and intranasal pathways and inoculation via the maternal placenta28•37• 
All extralabyrinthine inoculation routes differ in bypassing natural barriers and in the 
way the virus spreads to the cochlea. This introduces a variability into the 
experimental model we find unacceptable. It has been argued by several authors that 
irrespective of the inoculation route, viral affinity exists for various cochlear 
structures so the virus involved will leave a fingerprint on the affected cochlea. 
However, after intralabyrinthine/perilymphatic inoculation, a consistent 
perilymphatic inflammation is observed which can not be established in descriptions 
of the human cochlea in viral labyrinthitis. Although a selective viral affinity for 
other cochlear structures is apparent also after intralabyrinthine inoculation, we 
believe that the extent of perilymphatic involvement should be judged with caution 
when using this inoculation route. In spite of this limitation, we regard the 
intralabyrinthine inoculation model superior to other inoculation models. 
From the literature on experimental viral labyrinthitis the following specific affinity 
for cochlear structures can be derived for various viruses31-37 (Table 3): 
1 .  Atrophy of the stria vascularis in HSV, mumps virus and vaccina virus. 
2. Malformations of the tectorial membrane in HSV, mumps virus, rubeola virus 
and vaccina virus. 
3. Atrophy of the organ of corti in HSV, mumps virus, rubeola virus, influenza 
virus and vaccina virus. 
4. Loss of neuronal cochlear population in cytomegalovirus, HSV, mumps virus, 
rubeola virus and influenza virus. 
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Table 3: Experimental viral labyrinthitis: selective affinity of labyrinthine structures 
CMV HSV Mumps Rubeola Influenza Vaccina 
Perilymphatic 
Scala tympani +31.34.37 +3 1,33,36 onJl +ll.ll +Jl.)l +lLll 
Scala vestibuli +31 ,)4.37 +3 1 ,33.36 ? ? ? ? 
Endolymphatic 
Stria vascularis 01u<.11 +) 1 ,)3.36 +ll.ll 0 ll.l3 032,)3 +32,]] 
Reissner's membrane 03 1.34,37 03 1 ,33.36 +32.33 0 ll,3J 032,3] +32JJ 
Basilar membrane 031.34.37 03 1 .33,36 +32.33 0 31.33 032,33 +):!,)) 
Sensory end-organ 
Organ of Corti 03 1.)4,17 +3 1 ,33.36 +ll.ll +32.33 +32.33 +32J3 
Tectorial membrane 031 .)4.37 +31,33,36 +32.33 +32.33 +32,]3 +32,33 
Neural structures 
Ganglion cells 031 +34.37 +3 1.33.36 +J2J) +ll.JJ +32,)) 0 31.33 
Nerve fibres +3 1.34.37 +J J .JJ.Jfi +J:!.Jl +32.JJ +32, 33 0 J2.33 
( +: affected, 0: normal, ?: unknown) 
Only HSV and mumps virus are able to affect the same cochlear structures as are 
damaged in ISSHL. However, in mumps virus labyrinthitis, damage to the 
membranes surrounding the endolymphatic structures is observed, which is not 
described in HSV labyrinthitis and in ISSHL. 
We found histopathological changes in the cochlea after inducing viral labyrinthitis 
by the HSV - 1  to show a constant pattern of severe damage to the stria vascularis, 
atrophy of the organ of Corti, elevation or loosening of the tectorial membrane and 
inflammation of the neural fibres and ganglia. Reissner' s membrane kept its normal 
architecture. Elevation of the tectorial membrane might be caused by a disruption of 
the interdental cells, but this could also be secondary to elevation of the membrane. 
This pattern of pathological changes found in experimental HSV - 1  labyrinthitis bears 
a strong resemblance to the histopathology of ISSHL, although in these cases the time 
interval between occurrence of ISSHL and observation of cochlear histopathology is 
obviously much longer than in our experimental design. 
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Conclusions 
Experimental herpes simplex type I viral labyrinthitis provides a matching pattern of 
cochlear damage when compared to patients who have suffered from ISSHL. Severe 
deterioration of cochlear structure and function can occur without associated systemic 
manifestation of the viral infection, which is comparable to ISSHL too. These 
findings provide further support for the hypothesis that viral labyrinthitis might play 
an important role in the pathophysiology of ISSHL. The outcome of our study 
provides an adequate animal model for further elucidating the pathogenesis and 
treatment modalities in ISSHL. 
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antiviral treatment of experimmtal herpes simplex virus infection of the inner ear 
Stokroos RJ, Albers FWJ, Schirm J. Therapy of idiopathic sudden sensorineural 
hearing loss: antiviral treatment of expermental herpes simplex infections of the inner 
ear. Ann Otol Rhino! Laryngol. In press. 
59 
Introduction 
Therapy of Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is a subject of 
controversy. The high spontaneous recovery rate of ISSHL (45-65 %)1•2 and the low 
incidence of ISSHL (8- 14.6 per 1 00,000) in the Netherlands and Flanders3 make 
validation of empirical treatment modalities difficult, and its unknown 
pathophysiology impedes a rational approach. Earlier therapeutic efforts were aimed 
at restoring a supposed impaired cochlear blood circulation, but treatment results did 
not exceed placebo results4• Early application of corticosteroids has a modest 
beneficial effect on hearing recovery in ISSHL, but its interference with cochlear 
pathophysiology in ISSHL remains uncle;u5·6• 
In the literature, an important role of viral cochlear labyrinthitis in the pathogenesis of 
ISSHL is assumed, based on clinical and serological evidence and on a strong 
resemblance of cochlear histopathology found in experimental labyrinthitis and in 
post mortem temporal bone histopathology in ISSHL patients7• We have developed 
an animal model of ISSHL, in which herpes simplex virus type I (HSV- 1 )  elicits 
sudden sensorineural hearing loss in the guinea pig inner ear (chapter 5). In treatment 
of other manifestations of herpetic infections, the combination of corticosteroids and 
aciclovir seems to possess a synergetic therapeutical effect8. In this study an animal 
experiment was performed to evaluate the influence of steroids and aciclovir 
(Zovirax®), either as a monotherapy or as a combination therapy on cochlear function 
and cochlear pathology in experimental HSV- 1 labyrinthitis . The results may 
contribute to a more substantive approach to the treatment of ISSHL. 
Material and methods 
Sixteen healthy male albino guinea pigs (weight 400-500 g.) with a positive Preyer 
reflex received Halothane� general anaesthesia. Via a retroauricular incision, the 
tympanic bulla of the left ear was exposed and opened. An bevelled glass pipette 
(World Precision Instruments), with a tip measuring 50 micrometres in diameter was 
introduced through the round window membrane into the perilymphatic space, using 
a micromanipulator (World Precision Instruments). Via a microdosage system 
(Mitutoya), two microlitres of a herpes simplex virus type I (HSV- 1 )  suspension 
were injected in two minutes into the perilymphatic space. HSV - I, Mcintyre strain, 
was grown in monolayers of human embryonic lung fibroblasts, using culture 
medium consisting of minimal essential medium and Hanks' salts supplemented with 
fetal calf serum. When the fibroblasts showed an extensive cytopathic effect, the 
culture supernatant was cleared by centrifugation :it 2000 r.p.m. for 10 minutes. This 
cleared supernatant, which contained 8 x 104 TCID5o units per microlitre, was used 
for infecting the guinea pigs. 
Four groups were formed: 3 animals were inoculated with the virus suspension and 
remained untreated, 3 animals were inoculated with the virus suspension and were 
treated with prednisolone, 3 animals were inoculated with the virus suspension and 
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were treated with aciclovir (Zovirax®, GlaxoWellcome), 3 animals were inoculated 
with the virus suspension and treated with both aciclovir and prednisolone. An 
additional group of four animals received the culture medium only. Prednisolone was 
administered in a dosage of I milligram per kilogram body weight intraperitoneally 
once daily during 7 days, aciclovir was applied in a dosage of 10 milligram per 
kilogram body weight intraperitoneally 3 times daily during I week. Each day, 
auditory function was monitored using the Preyer reflex. Blood samples were 
obtained both prior to inoculation and just before sacrifice, and HSV antibody titers 
were determined in both samples in both samples in the following two different ways. 
Complement fixing HSV antibodies were measured by a modification of the 
Laboratory Branch Complement Fixation micromethod9, which can also be applied 
on sera from guinea pigs 10• HSV-specific IgG titres were determined by indirect 
immunofluorescence on acetone fixed HSV -infected cells, using fluorescein 
isothiocyanate-labeled goat anti-guinea pig IgG reagent (Soutern Biotechnology 
Associates Inc.). On day seven, all animals were sacrificed. Primary fixation took 
place by intralabyrinthine perfusion with 2.5% glutaraldehyde in a 0.08 molfL. 
sodium cacodylate buffer (pH =7.4). After dissection of the cochlea, immersion 
fixation with the same fixative was carried out during three hours. Decalcification 
took place in 1 0% EDT A-2Na (pH= 7 .4). Postfixation was performed using I %  Os04 
and 1 .5% K4Ru(Cn)6 followed by dehydration in graded alcohol. After embedding, 
midmodiolar sections of the cochlea were stained with toluidine blue and evaluated 
using light microscopy (Olympus OM2) and judged by a panel of four independent 
observers experienced in the evaluation of inner ear pathology. 
Results 
Observation of auditory function 
The Preyer reflex, estimating the presence of hearing, was positive before inoculation 
with HSV - 1  in all animals. Hearing loss occurred in the affected ear within 24 hours 
in all animals inoculated with HSV- 1 .  The animals inoculated with the culture 
medium showed no sign of hearing loss. 
In the untreated group, hearing did not recover. In the prednisolone treated group, 
hearing recovered by 7 days. In the aciclovir treated group, hearing did not recover. In 
the aciclovir I prednisolone treated group, hearing recovery occurred after 2-3 days. 
Serolo�ical evaluation 
No systemic symptoms of viral infection were observed in any of the animals. 
However, HSV-IgG seroconversions were demonstrated in all HSV inoculated 
animals and in none of the control animals. HSV-IgG titers in the second serum 
samples, of the infected animals, as measured by immunofluorescence, varied 
between 1 0  and � 80 (median titer 20). No HSV antibod1es were found when the less 
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sensitive complement fixation test was used. 
Light microscopic evaluation (Table l )  
I n  animals inoculated with the culture medium and i n  all contralateral ears o f  the 
HSV inoculated animals, the perilymphatic spaces showed no sign of bleeding or 
fibrosis. Reissner's membrane was intact. The stria vascularis showed its normal 
architecture. The supporting cells were normal and the outer and inner hair cells were 
intact. The tectorial membrane was in its normal position, the tunnel of Corti had its 
normal shape. Cochlear neural fibres and spiral ganglion cells were not affected. 
Table 1: Structural changes of the cochlea in experimental herpes simplex virus type I (HSV- 1 )  
labyrinthitis and its treatment. 
HSV-1 HSV-11 HSV-11 HSV-11 
prednisolone aciclovir prednisolone + 
aciclovir 
Scala vestibuli + 01+ + 01+ 
Scala tympani +I++ +I++ ++ + 
Scala media 0 0 0 0 
Reissner's 0 0 0 0 
membrane 
Stria vascularis ++I+++ ++ ++I+++ 01+ 
Supportive cells ++I+++ ++ +++ ++ 
Outer hair cells +++ ++I+++ +++ +I++ 
Inner hair cells +++ +++ +++ ++ 
Tectorial ++ ++ ++ + 
membrane 
Nerve tibres ++ + ++ 01+ 
Ganglion cells ++ + ++ 01+ 
(+++: destroyed, ++: damaged, +: slight damage, 0: normal) 
In animals inoculated with the HSV - 1  (fig. I ), we found some blood cells lying 
peripherally in the scala vestibuli. In the scala tympani, these cells were surrounded 
by a loose peripheral network of fibrosis. In the scala media, no blood cells or fibrosis 
were observed. Reissner's membrane was intact and in its normal position. The stria 
vascularis showed a disturbed architecture: the intermediate cell layer showed dilated 
blood vessels which were filled with erythrocytes. The stria vascularis was swollen 
62 
with the presence of increased intercellular spaces in the intermediate cell layer. An 
inflammatory infiltration was present in the stria vascularis and in the spiral ligament. 
Supportive cells were flattened or destroyed. Outer and inner hair cells were 
completely shrivelled up. The tunnel of Corti was not recognizable. The tectorial 
membrane was elevated from the organ of Corti and in some cases lying loose in the 
scala media but its shape remained unchanged. Both nerve fibres and ganglion cells 
showed some inflammatory infiltration. 
In the animals treated with prednisolone after inoculation (fig. 2), some blood cells 
were present in the apical portion of the scala vestibuli. This bleeding was more 
profound in the aciclovir treated group (fig. 3) and much Jess in the aciclovir­
prednisolone treated group (fig. 4). 
In the prednisolone treated group, the scala tympani showed a loose peripheral 
network of fibrosis lying peripherally in the basal coils of the cochlea. This fibrosis 
was more dense and accompanied by bleeding in the aciclovir treated group. In the 
aciclovir-prednisolone treated group, a very mild fibrosis lying peripherally in the 
basal coils was found. Reissner's membrane remained intact in all three groups. 
The stria vascularis showed dilated blood vessels and inflammatory cells in the 
animals treated with prednisolone and, more pronounced, in the animals treated with 
aciclovir. When both prednisolone and aciclovir were applicated, pathological 
changes were almost totally absent. 
The supportive cells were flattened and damaged in the animals receiving 
prednisolone. This was more pronounced in the animals receiving aciclovir as a 
monotherapy but considerably less in the apical coils of the animals receiving both 
treatment modalities. 
Outer hair cell damage was severe in the prednisolone treated group, profound in the 
aciclovir treated group and Jess severe in the prednisolone-aciclovir treated group, in 
which the apical windings of the cochlea were unaffected. Inner hair cells were 
completely destroyed in both groups receiving monotherapy, and were damaged in 
the basal coils in the group receiving combination-treatment. The tectorial membrane 
was elevated in both groups receiving monotherapy but remained attached to the 
cochlea in the animals receiving the combination therapy. 
A mild inflammatory reaction existed in nerve fibres and spiral ganglion cells of the 
animals receiving prednisolone-monotherapy, this reaction being greater in the 
animals treated with aciclovir only. In the group receiving the combination therapy, 
this reaction could not be established. 
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Figure 1 :  Light microscopy of a midmodiolar section of a guinea pig cochlea showing experimental 
herpes simplex virus type I labyrinthitis ( I  OOx). 
Extensive destruction of the organ of Corti and supporting cells (arrow). The stria vascularis shows 
severe morphological degeneration (asterisk). 
Figure 2: Light microscopy of a midmodiolar section of a guinea pig cochlea showing experimental 
herpes simplex virus type I labyrinthitis after treatment with prednisolone ( I  OOx). 
Diminished destruction of the organ of Corti and supporting cells (arrow). Less bleeding in the scala 
vestibuli (asterisk). 
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Figure 3: Light microscopy of a midmodiolar section of a guinea pig cochlea showing experimental 
herpes simplex virus type I labyrinthitis after treatment with aciclovir ( I  OOx). 
Severe destruction of the organ of Corti and supporting cells (arrows). Considerable bleeding in the 
scala vestibuli and scala tympani (asterisk). 
Figure 4: Light microscopy of a midmodiolar section of a guinea pig cochlea showing experimental 
herpes simplex virus type I labyrinthitis after treatment with prednisolone and aciclovir ( I  OOx). 
The organ of Corti and supporting cells are much less affected (arrow). The stria vascularis has an 




Preyer reflex monitoring was chosen because it provides a reproducable estimate of 
the presence of hearing without disturbance of the animal model, and in can be 
performed rapidly and repeatedly. In this study design, these advantages outweight 
the more precise estimate of hearing threshold obtained by measuring 
electrophysiological parameters1 1 • Herpes simplex virus type 1 labyrinthitis caused 
rapid hearing loss which recovered within 7 days of treatment with prednisolone. 
This is consistent with our clinical experience. Although the application of aciclovir 
alone did not lead to hearing recovery, the combined treatment of HSV - 1  labyrinthitis 
with both aciclovir and prednisolone led to earlier hearing recovery than observed 
with prednisolone as a monotherapy. 
Serological evaluation 
The experimentally induced HSV -1 labyrinthitis, causing both hearing loss and gross 
structural damage to the cochlea, followed an otherwise symptomless course which 
was not accompanied by the appearance of HSV specific complement fixing 
antibodies. However, the primary HSV infection in the inoculated animals could be 
confirmed by HSV-IgG seroconversion. Whether a non-primary local HSV infection, 
as might be present in ISSHL, can be detected by serological evaluation remains to be 
demonstrated. 
Light microscopic evaluation 
Histopathological changes in the cochlea after inducing viral labyrinthitis by HSV-1 
showed a consistent pattern of severe damage to the stria vascularis, atrophy of the 
organ of Corti, elevation or loosening of the tectorial membrane and inflammation of 
the neural fibres and ganglia. These pathological changes show a strong resemblance 
to those described in ISSHL, although in these subjects, the time interval between 
occurrence of ISSHL and observation of cochlear histopathology is obviously much 
longer than in our experimental design. This might be responsible for the differences 
between our experimental observations and descriptions of ISSHL post mortem 
histopathology in the literature7• 
Early application of corticosteroids can suppress the inflammatory reaction to HSV - 1 ,  
thereby limiting structural damage to the cochlea. However, significant destruction 
remains, perhaps explaining the modest success of ISSHL treatment with 
prednisolone. Application of antiviral medication as a monotherapy, aimed at the 
prevention of viral multiplicatiQn did not alter the devastating effects of HSV - I  
labyrinthitis. Perhaps viral spreading i s  already too extensive when using the 
perilymphatic inoculation pathway. Theoretically, the combination of prednisolone 
and aciclovir will not only lead to a suppressive effect of the inflammatory reaction 
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but also to a limitation of viral multiplication and spreading. In this study, the 
combination of both prednisolone and aciclovir seems synergistic in limiting cochlear 
damage compared with prednisolone application as a monotherapy: Jess damage 
occurred to the organ of Corti and the stria vascularis, especially in the apical 
windings of the cochlea. Also, the inflammatory reaction found in neural structures 
seems to be limited further by this combined treatment. 
Conclusions 
Histopathogical changes caused by experimental HSV - 1  labyrinthitis show a striking 
resemblance to histopathological changes described in ISSHL patients. Severe 
deterioration of cochlear function and of cochlear structures occurs, whilst no 
systemic manifestations of viral infection are observed. This provides further support 
for the hypothesis that ISSHL might be caused by a viral labyrinthitis, possibly 
involving the herpes virus family. Corticosteroids are able to aJieviate hearing Joss 
and to limit cochlear damage in experimental HSV-1  labyrinthitis. Adding aciclovir 
to prednisolone treatment provides earlier relief of the hearing Joss and further 
limitation of structural cochlear damage in experimental HSV - 1  labyrinthitis. 
This combination therapy has already proven its effectiveness in Ramsay Hunt 
syndrome and in herpes zoster oticus. It has also been proposed for treatment of 
Bell 's palsy12• The usefulness of early corticosteroid application in ISSHL has been 
reported in the literature. Our study results suggest a synergistic therapeutical effect 
of the combination of corticosteroids and aciclovir in the treatment of ISSHL. We are 
currently investigating this treatment modality in ISSHL patients in a randomized, 
double blind, placebo controJied clinical study. 
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Introduction 
Sudden sensorineural hearing loss is a symptom which can be ascribed to a variety of 
etiological factors. Often, no etiology can be identified and the hearing loss is 
considered to be idiopathic. Hypotheses explaining the idiopathic manifestation of 
sudden sensorineural hearing loss include a labyrinthine circulatory disturbance, a 
spontaneous labyrinthine membrane rupture or a subclinical viral labyrinthitis. 
Although the exact mechanism operational in the pathogenesis of Idiopathic Sudden 
Sensorineural Hearing Loss (ISSHL) remains obscure, circumstantial evidence is 
pointing at a subclinical viral labyrinthitis 1 • 
Magnetic resonance imaging (MRI) is usually performed in sudden sensorineural 
hearing loss because its superior soft tissue contrast is able to distinguish underlying 
pathology, such as cerebellopontine angle lesions2• Advancements in MRI, especially 
the use of gadolinium contrast (Gd-MRI), refinement of its resolution and the 
application of special sequences, such as three-dimensional Fourier transformation­
constructive interference in steady state (3DFf-CISS) MRI or fast spin-echo (FSE) 
MRI might provide further insight in labyrinthine pathology in ISSHL. 
In labyrinthitis, disruption of the blood-labyrinth barrier causes protein accumulation 
in the intralabyrinthine fluid compartment, which might be detected as a high signal 
intensity on unenhanced T l-weighted MR images. Application of gadolinium 
contrast causes further intralabyrinthine enhancement by contrast leakage and 
accumulation. Some authors suppose that the distribution of labyrinthine 
enhancement is related to tonotopic projection of the hearing loss on the cochlea3• 
Mark, Seltzer et aJ.3.4 reported seven patients with sudden hearing loss presumed to be 
idiopathic, in which a resolving hyperintensity of the inner ear was seen using T ! ­
weighted images before and after gadolinium contrast application. Four other patients 
were suffering from a proven viral labyrinthitis, and showed a similar picture. 
Busaba and Rausch5 reported Gd-MRI results of 14 ISSHL cases with an abnormal 
auditory brainstem response (ABR). In 1 case, enhancement was found in the distal 
portion of the internal auditory canal, which resolved in 6 weeks with concomitant 
hearing recovery. In all the other cases, Gd-MRI was normal. 
Albers, Demuynk and Casselman6 reported an MRI study of the inner ear in 5 ISSHL 
cases in whom hearing loss had existed for 5 months, using 3DFr-CISS MRI. The 
study was aimed at investigating late sequelae of ISSHL in the membraneous 
labyrinth. No enhancement or osseous obliteration of the perilymphatic spaces was 
found, which is often described in hearing loss associated with blood circulation 
disturbances and in bacterial labyrinthitis. Study results provided support for a viral 
labyrinthitis in the pathogenesis of ISSHL. 
In Bell's palsy, Gd-MRI enhancement has been described along the course of the 
seventh cranial nerve7•8, and in Ramsay-Hunt syndrome Gd-MRI enhancement of the 
inner ear and seventh and eight cranial nerves was found9• 10• 1 1 • These findings were 
interpreted to denote inflammation of labyrinthine and neural structures. 
Although the first two reports indicate the ability of Gd-MRI in detecting labyrinthine 
and neural inflammatory changes in the early phase of ISSHL, its sensitivity is 
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unknown. 
We report early findings in the human labyrinth in ISSHL as detected by Gd-MRI, 
in relation to the severity of the hearing loss, eventual vestibular involvement and 
time interval between occurrence of ISSHL and MR imaging. 
Subjects and methods 
Thirty-six ISSHL patients took part in a prospective multicentre clinical trial aimed at 
investigating therapy with prednisolone I aciclovir versus prednisolone I placebo. We 
defined ISSHL as follows: ( I )  Sensorineural hearing impairment of unknown 
etiology. (2) Hearing impairment occurring within 24 hours. (3) Hearing impairment 
averages at least 30 dB for three subsequent one octave steps in frequency in the 
standard pure-tone audiogram. Exclusion criteria were: ( I )  A history of fluctuating 
hearing impairment. (2) A compromised otological history. 
In all patients magnetic resonance imaging was performed. In one patient a 
schwannoma originating from the vestibular nerve was detected within the inner 
auditory canal. For adequate MR imaging of labyrinthine pathology, the following 
requirements were applied: 
I .  Imaging is obtained by using a superconductive active shielded magnet of at 
least 1 .0 Tesla. 
2. Sequences consist of both gadolinium-enhanced T 1- and unenhanced T ! ­
weighted images. 
3. Slice thickness is 3 millimetres at maximum, excluding an eventual interslice 
gap. 
MR images of 27 patients fulfilled these criteria and were included. Patients were 
investigated using a Philips Gyroscan S I S  MR, a Siemens Magnetom Impact MR , a 
Siemens Magnetom Vision MR and a Signa MR. 
The scans were judged independently by the authors. Visualisation of the 
membranous labyrinth on MRI was interpreted along the guidelines listed in table 1 12• 
The following variables were correlated to the MRI findings: 
I .  Severity of hearing loss, as indicated by the Fletcher index. 
2. Vestibular involvement, defined as an abnormal electronystagmographic 
response on caloric or rotational chair provocation. 
3 .  Time interval between occurrence of iSSHL and imaging. 
7 1  
Table 1: Value of different MRI sequences in patients with membranous labyrinth pathology": 
Tl T2 TlGd Tl+T2 Tl+TlGd 
Labyrinthitis - - + - ++* 
Schwan noma ++ - + ++ ++* 
Cholesterol + + + ++* + 
granuloma 
Fibrous dysplasia ++ ++ ++ ++ ++ 
LVAS ++ ++ ++ ++ ++ 
Cogan's - - - -
syndrome 








( +) pathology was recognized, additional information provided by other sequences required to make 
exact diagnosis. 
( ++) diagnosis can be made with this single sequence or pair of sequences alone. 
(*) optimal single sequence or pair of sequences in this case. 
LV AS large vestibular aqueduct syndrome. 
Results 
In ISSHL, T l -weighted unenhanced and gadolinium enhanced MRI showed no 
abnormal enhancement in either the labyrinth or the cochleovestibular nerve in 26 of 
27 patients (fig. 1 ). In one patient we observed mild enhancement in the basal and 
middle cochlear turns on T ! -weighted images before and after gadolinium 
application. Constructive interference in steady state (CISS) sequences obtained in 
this study confirmed an earlier report6, showing no osseous or fibrous obliteration of 
the perilymphatic spaces in ISSHL. 
In 1 5  cases, the right ear and in 1 2  cases the left ear was involved. No cases of 
bilateral hearing loss were present. Hearing loss averaged 73.6 dB Fletcher index 
(range 40- 1 20). Vestibular involvement was present in 6 cases. MRI was performed 
within one week after hearing loss occurred in 4 cases, within two weeks in 1 3  cases, 
within one month in 1 9  cases and within six weeks in 25 cases. In the patient 
showing abnormal labyrinthine enhancement, profound deafness ( 1 20 dB Fletcher 
index) with vestibular involvement had occurred 44 days before imaging. 
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Figure 1: Unenhanced (fig. I a) and gadolinium enhanced (fig. I b) MRI of the inner ear in ISSHL 






ISSHL is characterized by its unknown etiology. Accumulating circumstantial 
evidence implies a subclinical viral labyrinthitis in eliciting ISSHL. Acute 
labyrinthitis can be recognized on gadolinium enhanced T l-weighted MR images as a 
result of gadolinium accumulation in the membraneous labyrinth caused by 
breakdown of the blood-perilymph barrier12• However, in our series of ISSHL 
patients labyrinthine enhancement on MRI is a rare finding. MRI enhancement of 
labyrinthine structures in ISSHL depends on the intensity of the underlying 
inflammatory process. In our study, in only 4 cases MR imaging was performed 
within one week after initial presentation of symptoms. The prolonged time interval 
between the onset of ISSHL and the moment of imaging might explain in part the 
absence of labyrinthine enhancement in our patients. All patients reported in this 
study were treated with the anti-inflammatory drug prednisolone and double-blindly 
with the antiviral drug aciclovir or with placebo, aimed at dampening the underlying 
labyrinthitis and thereby at improving hearing recovery prognosis1 3• 14• Since the early 
treatment of ISSHL is of prognostic value, therapy was started as soon as possible 
after occurrence of hearing loss, and imaging was obtained afterwards. However, the 
anti-inflammatory therapy might have attenuated the viral labyrinthitis in our patients, 
making it undetectable by MRI. 
The severity of the hearing loss and vestibular involvement provides an indication of 
the intensity of the labyrinthitis. ISSHL cases reported in this study represent the 
normal spectrum of clinical presentation of the disease when severity of the hearing 
loss and vestibular involvement are concerned 15 • Labyrinthine enhancement in our 
study exclusively occurred in a patient with severe audiovestibular �ymptoms 
indicating a profound labyrinthitis. In cases of mild hearing loss without vestibular 
involvement, MRI detection threshold might be too high. 
Earlier reports confirm the ability of MRI to identify an underlying inflammatory 
process in ISSHL but provide no estimate of its sensitivity. The definition of ISSHL 
in this study is in accordance with the definitions applied in earlier imaging studies3•5• 
However, in these studies, additional selection criteria such as an abnormal auditory 
brainstem response (ABR) may have provided a selection bias, providing unjustified 
optimism in the ability of MRI to detect a labyrinthitis in ISSHL. 
Traditionally, MRI is used to exclude cerebellopontine angle lesions in sudden 
hearing loss. It has again proven this ability in our study. However, MRI may play an 
important role in either identifying or excluding an extensive part of the differential 
diagnosis of sudden hearing loss. Intralabyrinthine localized lesions (e.g. 
schwannoma, autoimmune labyrinthitis in Cogan's syndrome), congenital 
malformations (e.g. large vestibular aqueduct syndrome) or central lesions (e.g. 
multiple sclerosis) can be detected by MRI12• Although MR imaging seems obligatory 
in each case of iSSHL, this is not common practice yet16• 
MRI should be performed as early as possible after ISSHL has occurred, thereby 
avoiding possible labyrinthine enhancement attenuation by interference with therapy 
or by spontaneous recovery. 
74 
When MRI is performed along the recommendations summarized in table 2, the 
requirements mentioned previously can be certified. Adequate judgement of 
labyrinthine enhancement is possible only when slice thickness of the T l-weighted 
images is (less than) 3 mm. An inters!ice gap should not be used when investigating 
an organ as small as the inner ear. At least Tl-weighted images before and after 
gadolinium contrast application should be obtained of the labyrinth and 
cerebellopontine angle, but we recommend a complete imaging sequence of the 
auditory pathway in each ISSHL case. To reduce misinterpretation by partial volume 
effects, both axial and coronal slices should be made. Further insight in the 
distribution of labyrinthine pathology might be obtained by using three-dimensional 
reconstruction techniques. We have used gadolinium contrast in a dosage of l mg/kg 
body weight in this study, and we have no experience in increasing the gadolinium 
dosage. Theoretically, a higher gadolinium dosage might be able to ease detection of 
labyrinthine enhancement in ISSHL. 
Table 2: Recommendations for Magnetic Resonance Imaging in Idiopathic Sudden Sensorineural 
Hearing Loss 
ISSHL related MRI related 
- investigate each case of ISSHL - use slice thickness s 3 mm 
- investigate as soon as possible after hearing loss - use no interstice gap 
- investigate preferably before treatment is started - obtain at least T l  and T I Gd images 
- study the complete auditory pathway - obtain axial and coronal slices 
Conclusions 
Magnetic Resonance Imaging in ISSHL is valuable to exclude cerebellopontine angle 
lesions presenting as sudden hearing loss. In daily clinical practice, its sensitivity to 
identify an intralabyrinthine or neural inflammatory process in ISSHL is low. Such a 
process might only be observed in the very early phase after ISSHL occurred and 
might be attenuated by anti-inflammatory therapy. Therefore, we recommend an 
imaging protocol in which at least unenhanced T l - and gadolinium enhanced T l ­
weighted MR images are acquired as early as possible i n  ISSHL, preferably before 
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Introduction 
Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) annually occurs in 8-
14.6/ 100.000 persons in the Netherlands and Flanders but its pathophysiology and 
therapy remain subject to contradiction1•2• 
Etiology 
A subclinical viral labyrinthitis was postulated to elicit ISSHL from observations of 
an upper respiratory infection preceding the hearing Ioss3• This hypothesis was 
supported by reports of seroconversion of viral antibody titers for several viruses in 
ISSHL 4-6• MRI studies of the inner ear indicate-the presence of a viral labyrinthitis7•8 • 
Postmortem cochlear histopathology of ISSHL patients has shown pathological 
changes resembling those encountered in viral labyrinthitis9'1 1 • Herpetic viral 
labyrinthitis provides a matching histopathological pattern of cochlear damage when 
compared to patients having suffered from ISSHL, and reactivation of a latent herpes 
infection was postulated to cause ISSHL12• Herpes simplex virus type I (HSV- 1 )  has 
been demonstrated to remain latent in healthy human spiral ganglia13• We have 
elicited sudden hearing loss in the guinea pig by inducing HSV - 1  labyrinthitis and 
found cochlear histopathology to resemble cochlear histopathology in ISSHL 
(Chapter 5). Experimental viral labyrinthitis by other virus families possesses a less 
comparable affinity to various cochlear structures14'18• Based on these findings, we 
have adopted the hypothesis that ISSHL might be caused by a reactivation of a 
subclinical labyrinthine infection, possibly by HSV - 1 .  
Therapy 
Therapy of ISSHL is disputable also. Its low incidence impedes empirical control of 
all treatment modalities possible. The early application of corticosteroids in ISSHL 
improves hearing recovery prognosis to a limited extent19·20• Other treatment 
modalities either are lacking proper evaluation or are ineffective2 1 • In experimentally 
induced HSV - I  labyrinthitis in the guinea pig we found hearing to recover after 
application of prednisolone. Cochlear damage seemed to be limited by the anti­
inflammatory properties of corticosteroids. Based on the hypothesis of viral 
reactivation we also used a combination therapy consisting of aciclovir (Zovirax®) 
and prednisolone. After this combination therapy we observed further limitation of 
cochlear damage and earlier hearing recovery (Chapter 6). This therapy modality is 
also favoured in other herpetic infections22·23 but has not been reported in ISSHL. In 
this study, ISSHL therapy consisting of corticosteroids and aciclovir is applied in a 
prospective, randomized, double-blind clinical trial to make evaluation of this 
treatment modality possible. 
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Patients and methods 
In- and ex clusion criteria 
Patients participating in the trial met the following inclusion criteria: ( l )  cochlear 
hearing loss of unknown etiology; (2) hearing loss averages at least 30 dB HL for 
three subsequent one octave steps in frequency in the standard pure tone audiogram; 
(3) hearing loss occurring within 24 hours; (4) blank otological history. Exclusion 
criteria were: ( l )  hearing loss occurring more than 14 days ago; (2) contraindications 
for the use of either prednisolone or aciclovir. 
Diagnostic protocol 
The interval between the occurrence of ISSHL and the onset of treatment is of 
prognostic significance21 • The necessity for early treatment of ISSHL may implicate 
the erroneous treatment of various underlying conditions leading to a sudden loss of 
inner ear function that can only be identified by time consuming diagnostic 
procedures. Although most conditions are rare, their consequences might be 
important. Therefore, we use an extensive diagnostic protocol in each case of sudden 
hearing loss .. After diagnostic samples have been taken, a provisional diagnosis of 
ISSHL is made and treatment is initiated. When a cause for sudden hearing loss could 
be identified later, patients were excluded from the study. 
lnfonned consent 
Patients received oral explanation by the treating physician and written information 
by the investigator. They signed an informed consent, designed according to 
European Good Clinical Practice regulations before participating in the study. 
Design 
This study was designed as a prospective, multicenter, randomized, double-blind, 
placebo controlled clinical trial. A multicenter approach was chosen because the low 
incidence of ISSHL makes inclusion of a sufficient number of patients difficult. In 
each participating hospital, the medical ethical committee approved of the trial 
protocol. 
ISSHL patients were admitted during one week for treatment. Randomization was 
performed by the hospital pharmacist. Treatment and follow-up were performed 
double-blindly. Patients were divided in two groups. Both groups were treated 
intravenously with prednisolone in a dosage of 1 mg per kg body weight on day one, 
to be diminished in equal steps during seven days to 0 mg. One group received 
aciclovir intravenously in a dosage of 10 mg per kg body weight, three times daily for 
seven days, the other group received placebo. Aciclovir or placebo was given in 
identical bottles labelled "ISSHL-trial". Outpatient follow-up consisted of four 
consultations, 1 week, 3, 6 and 12 months after discharge. After completion of the 
study, participating patients, treating physicians and investigators were informed 
whether aciclovir or placebo had been received. 
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Subjective parameters 
Patients were asked to judge their hearing recovery, tinnitus intensity, pressure 
sensation and dizziness. Hearing could be categorized as worsened, equal or 
improved. Tinnitus, pressure sensation and dizziness could be categorized as absent, 
mild, moderate or severe. These parameters were recorded before and after 
hospitalization, and during outpatient follow-up. 
Laboratory evaluation 
Laboratory investigations were aimed at excluding the presence of an infectious, 
inflammatory or autoimmune process or a coagulopathy. An extensive virus 
serological evaluation was performed using paired blood samples and a 
nasopharyngeal swab or aspirate. Herpes simplex viruses, varicella zoster virus, 
cytomegalovirus, Ebstein-Bar virus, mumps virus, measles virus and chlamydiae 
were evaluated using specific lgG and lgM detection. Rubella virus was evaluated 
using IgM detection and hemagglutinase reaction (HAR). Mycoplasma pneumoniae 
was evaluated using IgM and complement fixing reaction. Influenza and 
parainfluenza viruses, rs-virus and coxiella burnetii were evaluated using 
complement fixing reaction. 
Audiometric parameters 
The following quantitative parameters were used to evaluate inner ear function on 
presentation: 
( 1 )  Pure-tone audiometry; (2) Speech audiometry; (3) Brainstem evoked response 
audiometry; (4) Nystagmography by caloric and torsion swing provocation. 
Pure-tone and speech audiometry were repeated at discharge, and on an outpatient 
basis after one week and after three, six and twelve months. 
Data collection and statistical processing 
A case record form was used for data collection. Data processing took place using an 
ffiM compatible personal computer. Statistical processing was performed using SPSS 
release 7.0 (SPSS Inc.). Data entry was controlled by frequency tables. An assumed 
normal distribution of the parameters were verified by Kolmogorow-Smirnow tests. 
Performing a clinical trial in a relatively small patient cohort implies a sensitivity to 
unequal distribution of variables of prognostic significance, despite careful 
randomisation. In ISSHL, severity of the hearing loss and involvement of the 
vestibular apparatus are indicators of an unfavourable prognosis. The proportion of 
patients with vestibular involvement did not differ significantly between both groups. 
The severity of initial hearing loss did significantly differ between both groups but 
approximated a normal distribution in each group. Between groups hearing recovery 
results were analyzed using MANOV A covariate analysis, controlling for unequal 
initial hearing loss severity. The other variables were normally distributed and 
statistically processed using t-tests for independent samples and Chi-square analysis. 




Between 1 994 and 1 996, 44 Dutch and Flemish ISSHL patients were included in the 
study. Twenty-two patients received aciclovir and prednisolone and 22 patients 
received placebo and prednisolone. One patient was diagnosed as having a vestibular 
schwannoma and was excluded after randomisation. Subsequently, 43 patients were 
available for evaluation: 22 in the aciclovir/prednisolone and 2 1  in the 
placebo/prednisolone group. All cases of hearing loss were unilateral. Gender 
distribution was equal within both groups. In the whole group, age distribution 
ranged from 1 1 -7 1 years, averaging 45.5 years with a preponderance for the fourth 
and fifth decades. In the aciclovir treated group age averaged 42.9 years, in the 
placebo group age averaged 45.7 years (p > 0.05). Within one month before hearing 
loss occurred, complaints of an upper respiratory infection had been present in 6/22 
patients receiving aciclovir and in 7/2 1 patients receiving placebo (p > 0.05). In the 
whole population, a recent upper respiratory infection occurred in 1 3/43 patients 
(30%). A history of herpes labialis infection was found in 1 1143 patients (26%) and a 
history of herpes zoster infection was found in 3/43 cases (7%). The occurrence of 
previous infections was equally distributed between aciclovir and placebo treated 
patients. On average, the hearing loss had been present for 4 days before specialist 
consultation took place (range 0- 1 2  days). Patients delay did not differ between 
aciclovir and placebo treated patients. Median hearing loss occurred within 5 minutes 
in the whole group. In 9 cases, the hearing loss was present at awakening. No 
seasonal influence was established on occurrence of hearing loss in our patients. 
Adverse effects 
The following events were noticed during treatment: 4 patients complained of a 
headache, of which 3 received placebo and 1 received aciclovir. Slight to moderate 
nausea occurred once in the placebo and once in the aciclovir group. In the placebo 
group, 1 patient complained of stomach pain and 1 patient developed a reversible 
high blood glucose level. These two side effects were both interpreted to be the result 
from prednisolone administration. No specific aciclovir side effects were observed. 
Virus serology 
An intensive effort was made to demonstrate the presence of systemic viral infection. 
Although in none of our patients clinical symptoms of viral infection were found, in 
5143 patients serological signs of viral infection were present. A raised IgM antibody 
titer against varicella zoster virus was found in one patient. Seroconversion against 
rubella virus occurred once, and signs of an active, non primary Ebstein-Bar virus 
infection was demonstrated once also. A dubious IgM reaction against mumps virus 
existed in one patient, and in another patient, parainfluenza virus type 3 was cultured 
from the nasopharynx, without a concomitant rise in antibody titer. 
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Subjective parameters (fig. 1 a-d) 
After one week of treatment, 1 5/22 (68%) of patients receiving aciclovir and 9121 
(43%) patients receiving placebo noticed hearing improvement {p > 0.05) (fig. 1 a).  
Figure la: Hearing categorized as "improved" by 43 ISSHL patients (p > 0.05). 
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In the remaining patients, hearing was judged to have remained unchanged. Hearing 
was not categorized as worsened after treatment in both groups. Most patients 
experienced hearing recovery during the first two weeks after hearing loss occurred. 
During follow-up, subjective hearing recovery took place in another 1 0/43 (23%) of 
patients. No significant differences were observed in hearing recovery between both 
groups. 
Tinnitus appeared to be the most discomforting symptom to accompany ISSHL 
(fig. 1 b). 36/43 patients (84%) experienced tinnitus, either preceding, coinciding with 
or following hearing loss. Tinnitus persisted for 6 months in 24/43 (56%) of patients. 
Twelve months after hearing loss., 1 7/43 ( 40%) of patients still experienced tinnitus. 
Severity of tinnitus did not differ significantly among the categories mild, moderate 
and severe. No differences in tinnitus complaints were found between aciclovir and 
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placebo groups. Application of aciclovir did not change tinnitus prognosis. 
Figure lb: Tinnitus categorized by 43 ISSHL patients (p > 0.05). 
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A pressure sensation on the affected ear was present in 21/43 patients (49%)(fig. l c). 
In 6 cases, this sensation preceded the hearing loss, in 7 cases it accompanied the 
hearing loss and in 8 cases it was noticed afterwards. In 6 cases pressure was judged 
to be mild, in 1 2  cases it was moderate and in 3 it was severe. In general, the 
prognosis of the pressure sensation was favourable: one year after the hearing loss, it 
was judged to be mild in 3 cases, moderate in 1 and severe in 2. Aciclovir or placebo 
treatment did not possess a statistically significant influence on this symptom. 
Hearing loss was accompanied by a sense of disequilibrium or vertigo in 20/43 cases 
(47%) (fig. l d). In 1 1  cases this sensation became apparent after hearing loss 
occurred, in 7 it accompanied hearing loss and in 2 it preceded hearing loss. 
Vestibular complaints resolved quickly. The prognosis of vertigo was good: 1 2  
months after hearing loss, 4 patients noticed a mild sense o f  disequilibrium. 
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Figure ld: Vertigo I postural instability categorized by 43 ISSHL patients (p > 0.05). 
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Audiometric parameters (Fig. 2a-e, fig 3a,b) 
follow-up 
Hearing thresholds versus follow-up interval, as measured by pure-tone audiometry in 
dB Fletcher index (FI) for each patient receiving either aciclovir or placebo are 
depicted in figures 2a and 2b. 
Hearing loss (dB FI) one week, two weeks and 12 months after ISSHL versus initial 
hearing loss are plotted for each individual case in figures 2c, 2d and 2e. 
Pure-tone audiometry was used to categorize hearing recovery (fig. 3a). A hearing 
recovery larger than 10 dB FI within a follow-up interval was categorized as hearing 
improvement, a recovery of 10 dB FI or less was categorized as an unchanged 
hearing. 
After treatment, in 1 8/43 (42%) patients a hearing recovery of more than 1 0  dB FI 
occurred. Two weeks after hearing loss, this was achieved by 28/43 (65%) of 
patients. One year after hearing loss, 34/43 (79%) of patients had obtained more than 
10 dB FI hearing recovery. Differences in hearing improvement between aciclovir 
and placebo treated patients were not significant (p > 0.05). 
Pure-tone audiometry was used also to quantify hearing recovery (fig. 3b). 
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Figure 2a: Hearing recovery in dBHL (FI) in 22 ISSHL patients receiving aciclovir/prednisolone. 
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Figure 2b: Hearing recovery in dB HL (Fl) in 21 ISSHL patients receiving placebo/prednisolone. 
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Figure 2c: Hearing recovery after one week versus initial hearing loss (dBHL Fl) in 43 ISSHL 
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Figure 2d: Hearing recovery after two weeks versus initial hearing loss (dBHL Fl) in 43 ISSHL 
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Figure 2e: Hearing recovery after twelve months versus initial hearing loss (dBHL FI) in 43 ISSHL 
patients, treated with either aciclovir/ prednisolone (A) or placebo/prednisolone (0). 
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Figure 3b: Hearing recovery by pure tone audiometry in 43 ISSHL patients (p > 0.05). 
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On admittance, hearing loss averaged 79 dB FI (n=43). When treatment was 
completed, hearing had improved to 64 dB FI, further improving to 58 dB FI two 
weeks after hearing loss had occurred and to 50 dB FI 3 months after hearing loss. 
Six months after hearing loss, hearing thresholds averaged 48 dB FI and 12 months 
after hearing loss, 46 dB Fl. In the aciclovir/prednisolone treated group, on 
presentation, hearing Joss averaged 67 dB Fl. Hearing Joss after one week of 
treatment averaged 55 dB FI, after 2 weeks 48 dB FI, after 3 months 43 dB FI, after 6 
months 42 dB FI and after 1 2  months 44 dB Fl. In the placebo/prednisolone treated 
group, on presentation hearing loss averaged 9 1  dB Fl. Hearing Joss after one week of 
treatment averaged 74 dB FI, after 2 weeks 67 dB FI, after 3 months 57 dB FI, after 6 
months 54 dB FI and after 1 2  months 49 dB Fl. 
In our clinical experience, prognosis is unfavourable in case of profound hearing loss. 
In 14/43 patients, initial pure-tone audiometry revealed a hearing Joss > 100 dB (FI). 
9 1  
Patients with an initial hearing loss � I 00 dB FI had a better hearing recovery 
prognosis compared to patients with a hearing Joss > I  00 dB FI irrespective of 
aciclovir application (p < 0.00 1 ). 
Despite of our double-blind randomization, more cases of profound hearing loss were 
allocated to the placebo-treated group than to the aciclovir treated group, thereby 
giving the erroneous impression of a significantly better hearing prognosis in the 
patients treated with aciclovir. When this difference in severity of initial hearing Joss 
was corrected for by performing covariate analysis, hearing recovery between the 
aciclovir/prednisolone and placebo/prednisolone treated patients did not differ 
significantly. 
ISSHL is often regarded as an otological emergency. It is assumed that when 
treatment is initiated in the very early phase of the hearing Joss, hearing recovery 
prognosis might be better. To verify this assumption, additional analysis was 
performed. We divided our patients into two subgroups: one in which treatment had 
begun within 24 hours after occurrence of hearing Joss (n= l 2), and one in which 
treatment delay had been longer, at maximum 12 days (n=3 1 ). Hearing recovery 
prognosis turned out to be comparable in both subgroups (p > 0.05). 
On average, a maximum speech discrimination score of 39% was achieved by 
patients when presenting with hearing loss. After one week of treatment, speech 
discrimination had improved to 56%, to reach 68% after 3 months. Speech 
discrimination ability did not improve further afterwards. The application of aciclovir 
had no effect on speech discrimination ability in ISSHL (MANOV A covariate 
analysis controlling for unequal speech discrimination distribution between both 
groups). 
Involvement of the vestibular organ in the hearing Joss, defined as an abnormal ENG 
response to caloric and/or rotational chair provocation of the affected ear, was present 
in 10/43 (23%) patients. Hearing loss and hearing recovery prognosis in this 
subgroup were comparable to hearing and hearing recovery in the population without 
vestibular involvement (p > 0.05). 
Discussion and conclusions 
ISSHL affects patients in the core of their existence and has serious repercussions on 
their social and professional functioning. 
A majority of ISSHL patients treated with prednisolone experience some subjective 
hearing recovery. Most do so after one week of treatment. In our study, aciclovir 
treated patients did not experience hearing recovery earlier or more often. When 
evaluated by audiometry, hearing recovery prognosis did not benefit from the 
application of aciclovir. Subjective hearing improvement closely matched hearing 
improvement evaluated by pure-tone audiometry (fig. l a  and 3a). A majority of 
patients suffer tinnitus, which has a poor prognosis, and turns out to be one of the 
lasting disturbing consequences of ISSHL. Application of aciclovir did not change 
tinnitus prognosis. Frequent concomitant complaints are a pressure sensation on the 
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affected ear and a sense of disequilibrium or vertigo. Both symptoms have a 
favourable prognosis, irrespective of aciclovir use. 
Our ISSHL patients, treated with prednisolone, achieved a better hearing recovery 
compared to untreated ISSHL patients reported previousl/1 •  Although they are non­
randomized groups, both share important characteristics. With this limitation in mind, 
our findings provide some additive support for earlier reports recommending the use 
of corticosteroids in ISSHL. 
Prognostic factors in ISSHL mentioned in the literature are vestibular involvement, 
severity of initial hearing loss and audiogram shape. Prognosis of hearing loss with or 
without involvement of the vestibular organ was comparable in our patients, although 
vestibular involvement has been suggested to indicate a more elaborate labyrinthitis 
carrying a relatively unfavourable prognosis2• In our patients, in case of severe or 
profound hearing loss, the chances for hearing to recover are poor, in cases of mild or 
moderate hearing loss, the chances of hearing recovery are better. In severe or 
profound hearing loss, cochlear damage is probably already too extensive for therapy 
to have a beneficial effect. Pure-tone audiogram shape was difficult to categorize in 
our patients. We were not able to establish a relationship between hearing recovery 
prognosis and pure-tone audiogram shape. 
In ISSHL, the delicacy of the structures involved makes elucidation of- and 
interference with its pathophysiology difficult. In our experience, no truly successful 
treatment regimen can be offered to the ISSHL patient, despite a mild beneficial 
effect of corticosteroids. Although we have not been able to ascertain a therapeutic 
value from the appliclltion of aciclovir in ISSHL in this study, some methodological 
limitations are apparent which might explain our results in part. 
Despite a multicenter approach covering the whole Dutch language region (2 1 .5 
million inhabitants) the patient group under investigation might have been too small 
to achieve statistical significance. Almost every study concerning ISSHL therapy 
suffers from this limitation, because of its low incidence, especially when in- and 
exclusion criteria are applied strictl/1• Secondly, to prove efficacy of a therapeutic 
modality in ISSHL it has to perform significantly better than the high spontaneous 
recovery rate found in ISSHL, reported between 40-65%. Thirdly, we experienced 
difficulty in defining desired outcome after therapy. Our efforts to perform a power 
analysis failed because the outcome measurements available are only a rough 
estimate of the sense of hearing. Most patients experience some hearing recovery but 
a minority recovers completely. Even if a few decibels are gained, speech 
discrimination ability is often impaired and the affected ear is no longer useful. 
Fourthly, despite double-blind randomization we failed to control for severity of 
initial hearing loss in this study. In future ISSHL research, we consider using forward 
stratification for initial hearing loss severity. 
We question whether the failure to demonstrate the effectiveness of aciclovir therapy 
in ISSHL should have implications for speculations on the pathophysiology of 
ISSHL. In our study, ISSHL occurred irrespective of age and sex, even in very young 
patients. We find acquired circulatory disturbances preceding ISSHL unlikely in this 
patient category. Despite an extensive search for the presence of a coagulopathy, an 
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auto-immune or other systemic illness in ISSHL, these could not be demonstrated in 
our patients. The unilateral occurrence of hearing loss makes a systemic pathogenesis 
less likely. The spontaneous occurrence of sudden hearing loss, even whilst asleep, 
makes a labyrinthine membrane rupture unattractive. Although no seasonal influence 
was demonstrated on occurrence of ISSHL, our patients were more frequently 
affected by an upper respiratory infection or by herpes labialis infection shortly before 
occurrence of ISSHL, compared to the normal population. A priming effect of a 
previous upper respiratory infection, leading to reactivation of a latent herpes virus 
infection which triggers an overwhelming inflammatory reaction in the labyrinth, 
damaging its delicate structures and causing hearing loss may be deduced from these 
findings, although the exact mechanism operational in viral reactivation and its 
interaction with inner ear immunity remain obscure. 
Extensive virus serological monitoring and culturing revealed only scarce indications 
of a viral infection in ISSHL, too incoherent to establish a causal relationship with the 
hearing loss. A non-primary herpetic infection, as may be present in ISSHL probably 
does not lead to a detectable antibody titer. 
In experimental herpes viral labyrinthitis, we found a synergistic effect of aciclovir 
and prednisolone treatment on hearing recovery and cochlear histopathology in the 
guinea pig inner ear. Since the experimental situation differs from clinical practice in 
excluding treatment delay, treatment of ISSHL might be divided in two phases. Only 
in the first, very early phase after ISSHL a combination therapy directed at the 
causative agent might be useful, combined with therapy aimed at dampening the 
inflammatory reaction. Most patients will present with hearing loss in a later phase 
and at this second phase, therapy should be directed primary towards a powerful 
suppression of the destructive inflammatory reaction, perhaps with an even higher 
corticosteroid dosage than we have used in this study. This two-phase theory in 
ISSHL therapy provides another argument for the commonly accepted fact that 
ISSHL should be regarded as an otological emergency. 
Recommendations 
Various therapeutic strategies have been applied in ISSHL, indicating the absence of 
a truly effective therapy. Our study results provide some support for earlier reports 
suggesting a beneficial effect on hearing recovery from the early application of 
corticosteroids in ISSHL. No beneficial effect from the application of aciclovir in 
ISSHL can be derived from this study, in contrast to our experimental findings. Based 
on this theoretical and experimental model of the pathophysiology of ISSHL, we 
propose a two-phase treatment regimen of ISSHL, which is based chiefly on the anti­
inflammatory properties of corticosteroids in ISSHL in the second phase whilst only 
in the first, very early phase after hearing loss, therapy is directed towards the 
possible provoking agent by adding aciclovir. 
Each new therapy of ISSHL should only be applied in an investigative setting. This 
makes a careful evaluation of the symptom sudden sensorineural hearing loss 
possible. Considerable methodological difficulties can be expected in performing 
such a trial, mainly due to the low incidence of ISSHL and to its high spontaneous 
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recovery rate. How to define recovery of ISSHL has proven to be difficult. Hearing 
recovery of ISSHL is certainly not equivalent to cure because often, considerable 
hearing damage remains. New therapeutic initiatives in ISSHL patients should be 
based on a thorough pathophysiological model before ISSHL patients are subjected to 
it. Reporting negative outcome of ISSHL therapy trials is obligatory because ISSHL 
patients are often exposed to therapeutic regimens lacking scientific support. 
Continuing a combination of research efforts aimed at the understanding of the 




I .  Stokroos RJ, Albers FWJ, van Cauwenberge P. Diagnosis and treatment of idiopathic sudden 
sensorineural hearing loss (ISSHL), A survey in the Netherlands and Flanders. Acta ORL Belg 
1 996; 50: 237-45. 
2. Stokroos RJ, Albers FWJ. The etiology of idiopathic sudden sensorineural hearing loss, a review 
of the literature. Acta ORL Belg 1 996; 50: 69-76. 
3. Van Dishoeck HAE, B ierman TA. Sudden perceptive deafness and viral infection. Ann Otol 
Rhino! Laryngol 1 957; 66: 963-80. 
4. Wilson WR, Veltri RW, Liard N, Sprinkle PM. Viral and epidemiological studies of idiopathic 
sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 1983; 9 1 :  653-8. 
5. Rowson KEK, Hinchcliffe R, Gamble DR. A virological and epidemiological study of patients 
with acute hearing loss. Lancet 1 975; I :  47 1 -3. 
6.  Wilson WR. The relationship of the herpes virus family to sudden hearing loss: a prospective 
clinical study and literature review. Laryngoscope 1 986; 96: 870-7. 
7 .  Albers FWJ, Demuynk KMNP, Casselman JW. Three-dimensional magnetic resonance imaging 
of the inner ear in idiopathic sudden sensorineural hearing loss. ORL 1 994; 56: 1-4. 
8.  Mark AS, Seltzer S, Nelson-Drake J ,  Chapman JC, Fitzgerald CD, Gulya AJ. Labyrinthine 
enhancement on gadolinium-enhanced magnetic resonance imaging in sudden deafness and 
vertigo: correlation with audiologic and electronystagmographic studies. Ann Otol Rhinal 
Laryngol 1992; 1 0 1 : 459-64. 
9. Schuknecht HF, Donovan ED. The pathology of idiopathic sudden sensorineural hearing loss. 
Arch Otolaryngol 1 986; 243: 1 - 15 .  
1 0. Yoon TH, Paparella MM, Schachern PA, Alleva M. Histopathology of  sudden hearing loss. 
Laryngoscope 1990; 100: 707- 1 5. 
I I . Sando I, Harada T, Loehr A, Sobel JH. Sudden deafness, histopathologic correlations in the 
temporal bone. Ann Otol Rhinal Laryngol 1 977; 86: 269-79. 
12 .  Veltri RW, Wilson WR, Sprinkle PM, Rodman SM, Kavesh DA. The implication of herpes 
viruses in idiopathic sudden hearing loss: primary infection or reactivation of latent viruses? 
Otolaryngol Head Neck Surg 1 989; 89: 1 37-4 1 .  
1 3. Fukada S, Furata Y ,  Takasu T, Suzuki S, Inuyama Y ,  Nagashima K .  The significance of herpes 
viral latency in the spiral ganglia. Acta Otolaryngol (Stockh) 1 994; Suppl 5 1 4: 108 10. 
14 .  Davis LE. Comparative experimental viral labyrinthitis. Am J Otolaryngol 1 990; I I : 382-8. 
1 5. Nomura Y, Kurata T, Saito K. Cochlear changes after herpes simplex virus infection. Acta 
Otolaryngol (Stockh) 1 985; 99: 4 1 9-27. 
1 6. Davis LE, Shurin S, Johnson RT. Experimental viral labyrinthitis. Nature 1 975; 254: 329-3 1 
96 
17 .  Nomura Y, Kurata T, Saito K. Cochlear changes after herpes simplex virus infection. Acta 
Otolaryngol (Stockh) 1 985; 99: 4 19-27. 
1 8. Nomura Y, Hara M, Kutara T. Experimental herpes simplex virus and cytomegalovirus 
labyrinthitis. Acta Otolaryngol (Stockh) 1 988; Suppl 457: 57-66. 
19. Wilson W, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden 
hearing Joss, a double-blind clinical study. Arch Otolaryngol 1980; 106: 772-6. 
20. Moskowitz D, Lee KJ, Smith HW. Steroid use in idiopathic sudden sensorineural hearing Joss. 
Laryngoscope 1 984; 94: 664-6. 
2 1 .  Stokroos RJ, Albers FWJ. Therapy of idiopathic sudden sensorineural hearing loss. A review of 
the literature. Acta ORL Belg 1 996; 50: 77-84. 
22. Adour KK, Ruboyianes JM, Von Doersten PG, By! FM, Trent CS, Quesenberry CP, Hitchcock 
T. Bell's palsy treatment with aciclovir and prednisolone compared with prednisolone alone: a 
double blind, randomized controlled trial. Ann Otol Rhino! Laryngol 1996; 105: 37 1-8.  
23.  Wood MJ,  Johnson RW, McKendrick MW, Taylor J, Mandai B K, Crooks J. A Randomized trial 
of acyclovir for 7 days or 2 1  days with and without prednisolone for treatment of acute herpes 




SUMMARY AND CONCLUSIONS 
99 
Summary 
Since the beginning of the 20th century, otologists have reported cases of sudden, 
unexpected sensorineural hearing loss. Today, in spite of the advancements in 
medicine, the pathophysiology of Idiopathic Sudden Sensorineural Hearing Loss 
(ISSHL) has not been elucidated and little can be offered to people struck by the 
hearing loss. 
In ISSHL, sensorineural hearing impairment or deafness develops during a very short 
period in otherwise healthy, and previously normally hearing persons. No population 
at risk can be identified. Generally, no predisposing factors are present and it is not 
uncommon for the hearing loss to be noticed at awakening. However, in our ISSHL 
patients an upper respiratory infection had been present within one month before 
ISSHL occurred in  30% of cases, although no seasonal influence could be established 
on occurrence of ISSHL. 
Most cases of ISSHL are unilateral but infrequently, both ears are involved. 
Spontaneous hearing recovery is reported in 45-65% of cases, although in a small 
minority of cases hearing will recover to functional levels. Hearing recovery 
prognosis depends on the initial severity of the hearing loss, its prognosis being more 
favourable in mild to moderate initial hearing loss and worse in profound initial 
hearing loss. Other factors of prognostic value might be the pure-tone audiogram 
shape and vestibular involvement, although these could not be confirmed in our 
clinical study. A majority of patients suffer from tinnitus, which often persists and 
can be extremely discomforting. Loss of hearing is often accompanied by a pressure 
sensation or by a mild pain in the ear, which sometimes radiates to the mandibular or 
temporal regions. This sensation might intensify under the influence of stress. Many 
patients experience a sense of disequilibrium but some are severely disabled by 
rotational vertigo, making it impossible to walk straight. Vestibular complaints 
usually disappear within a few weeks. 
The difficulties encountered in elucidating the pathophysiology of ISSHL and in 
designing an effective therapeutic strategy might be attributed to two factors. The first 
is the closed, delicate compartment formed by the inner ear, inhibiting access to study 
its pathophysiology. The second is the low incidence of ISSHL, which does not 
permit the establishment of the number of observations needed to evaluate new 
therapeutic modalities. All publications on ISSHL suffer from these limitations to a 
greater or lesser extent. Furthermore, the literature on ISSHL lacks comparability 
because no consensus exists on the definition of ISSHL. In this thesis, ISSHL is 
defined as follows: 
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l .  Perceptive hearing loss 
2. Etiology remains unknown after clinical, laboratory and imaging studies 
3. Hearing loss occurred within 24 hours 
4. Hearing loss is nonfluctuating 
5. Severity of the hearing loss averages at least 30 dB HL for three subsequent 
one octave steps in frequency as shown in the standard pure-tone audiogram 
6. Blank otological history. 
Our definition of ISSHL closely matches the diagnostic criteria used by the majority 
of ENT-surgeons in the Netherlands and in Flanders (Chapter 4). The restrictions 
mentioned earlier are apparent when reViewing the literature on ISSHL. 
Chapter 2 reviews the literature concerning the etiology of ISSHL. The applied 
definition of ISSHL is verified. The following hypotheses concerning the etiology of 
ISSHL are postulated in the literature: 
1 .  Disturbance of labyrinthine blood circulation 
2. Subclinical viral labyrinthitis 
3. Spontaneous labyrinthine membrane rupture 
4. Autoimmune mediated pathogenesis 
Experimental support, clinical evidence, laboratory and radiological findings and post 
mortem histopathological evidence categories are weighted for each etiological 
hypothesis. In the literature, insufficient evidence exists to assume a primary 
circulatory disturbance or a spontaneous labyrinthine membrane rupture to be 
responsible for ISSHL. An autoimmune mediated pathogenesis is an attractive 
explanation but lacks support. Circumstantial evidence suggests a viral infection of 
the labyrinth to provide an explaination for a majority of ISSHL cases. Therefore, a 
virally mediated pathophysiology of ISSHL is studied further in this thesis. 
Chapter 3 evaluates the literature on therapeutical strategies in ISSHL. The applied 
definition of ISSHL is verified. Trial designs are evaluated on comparativeness and 
on internal and external validity. Most therapeutic regimens in ISSHL are directed 
towards improving a suggested impaired labyrinthine blood supply or towards 
attenuation of a possible labyrinthine inflammatory process. No evidence of a therapy 
related effect is found from either improving cochlear blood supply or from 
thrombolysis. Two studies indicate a limited positive effect from the early 
administration of steroids on hearing recovery prognosis in ISSHL. Many other 
therapeutical modalities have been insufficiently evaluated. We recommend ISSHL 
treatment to take place in a carefully designed clinical trial with emphasis on 
comparativeness, internal and external validity. 
In Chapter 4, the results of a survey on diagnosis and treatment of ISSHL are 
reported, based on the opinion of 230 Dutch and 50 Flemish ENT -surgeons. 
Questions concern definition, incidence, diagnosis, therapy and possible etiology of 
ISSHL. Diagnostic criteria used to define ISSHL match our definition of ISSHL 
closely. The incidence of ISSHL in the Netherlands and in Flanders varies with 
preciseness in applying diagnostic criteria and is estimated 8/100,000 in the 
Netherlands and 1 4.6/ 100,000 in Flanders. Considerable differences are found in  
diagnostic accuracy and in therapeutic strategy in  ISSHL between individual ENT­
surgeons and between the Netherlands and Flanders. We recommend the use of a 
diagnostic protocol in ISSHL, based on a differential diagnosis, thereby preventing 
101  
diagnostic omissions. Therapy of ISSHL is considered fruitless 1 0  days after the 
hearing loss has occurred. Corticosteroids are often applied in ISSHL, but other 
therapeutic strategies and combinations of treatment are also used frequently. These 
regimens often lack a scientific basis. Treatment results are comparable to the 
spontaneous recovery rate reported in ISSHL. Fundamental research aimed at 
elucidating the pathophysiology of ISSHL might lead to further agreement on 
etiology and therapy of ISSHL. 
Chapter 5 presents an animal model of the pathophysiology of ISSHL. Establishing 
an animal model of ISSHL seems obligatory, since the delicacy of the structures 
involved inhibits further insight in the pathophysiology of ISSHL in humans. A viral 
labyrinthitis has been postulated to play a role in the pathophysiology of ISSHL, 
based on circumstantial evidence. Experimental viral labyrinthitis elicited by various 
virus families leaves a virus-specific pattern of cochlear damage. Herpes viruses 
provide the best matching pattern in the distribution of cochlear damage when 
compared to ISSHL postmortem cochlear histopathology. In this study, we elicit 
herpetic viral labyrinthitis in guinea pigs using perilymphatic inoculation with HSV-
1 .  A control group is inoculated with the culture medium only. Infection is confirmed 
by the measurement of HSV antibodies. Hearing and balance are monitored. Cochlear 
damage is evaluated by light and electron microscopy. In all HSV- 1 inoculated 
animals, rapid loss of hearing occurs, but balance remains undisturbed. 
Seroconversion takes place, but no systemic manifestations of herpetic infection are 
observed. The control group demonstrates no cochleovestibular or systemic 
symptoms. When comparing cochlear histopathology in ISSHL to experimental viral 
HSV -1 labyrinthitis, strong similarities are found: degeneration of the stria vascularis, 
destruction of the organ of Corti, loosening of the tectorial membrane and 
inflammatory changes in neural structures. Based on clinical and histopathological 
characteristics, experimental HSV - 1  labyrinthitis provides a suitable model for 
ISSHL. These findings provide further support for the hypothesis that viral 
labyrinthitis might play an important role in the pathophysiology of ISSHL. The 
outcome of this study provides an adequate animal model for further elucidating the 
pathogenesis and treatment modalities in ISSHL. 
In Chapter 6, the therapeutic efficacy of aciclovir (Zovirax®) and prednisolone in 
experimental herpes simplex type I (HSV - 1 )  viral labyrinthitis in the guinea pig is 
described. Experimental HSV- 1 labyrinthitis provides a model for ISSHL (Chapter 
5).  Corticosteroids improve hearing recovery prognosis in ISSHL but the effects of 
aciclovir are unknown. In this experiment, we induce HSV- 1 labyrinthitis in 1 2  
guinea pigs. Three animals receive n o  treatment, 3 receive prednisolone, 3 receive 
aciclovir and 3 receive both. Hearing, HSV- 1 antibody titers and cochlear pathology 
are evaluated. Corticosteroids ar�. able to alleviate hearing loss and to limit cochlear 
damage in experimental HSV-1 labyrinthitis. Adding aciclovir to prednisolone 
treatment provides earlier relief of the hearing loss and further limitation of structural 
cochlear damage in experimental HSV - 1  labyrinthitis. Our study results' suggest a 
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synergistic therapeutical effect of the combination of corticosteroids and aciclovir in 
the treatment of our ISSHL model. The value of this combined treatment for ISSHL 
patients remains to be demonstrated. 
In Chapter 7, the use of Gadolinium enhanced magnetic resonance imaging (Gd­
MRI) for identification of labyrinthine pathology in ISSHL is described. To this date, 
the role of MRI in ISSHL has been limited to excluding underlying pathology such as 
cerebellopontine angle lesions. Gd-MRI is able to detect the presence of a subclinical 
labyrinthitis in ISSHL. Its sensitivity in daily clinical practice is unknown. We 
describe Gd-MRI findings in 27 ISSHL patients taking part in a prospective 
multicenter clinical trial. MRI findings are related to the severity of the hearing loss, 
to vestibular involvement and to the time interval between occurrence of ISSHL and 
imaging. Pathological enhancement of the cochlea indicating a labyrinthitis is found 
in one case of ISSHL. In 26 cases, no pathological enhancement can be established. 
Study results indicate that magnetic resonance imaging in ISSHL is valuable for 
excluding cerebellopontine angle lesions which present as sudden sensorineural 
hearing loss. In daily clinical practice, its sensitivity for identification of an 
intralabyrinthine or neural inflammatory process in ISSHL is low. Such a process 
might only be observed during the very early phase following the occurrence of 
ISSHL and might be attenuated by anti-inflammatory therapy. Therefore, an imaging 
protocol is recommended in which at least unenhanced T 1- and gadolinium enhanced 
T I weighted MR images are acquired as early as possible in ISSHL, preferably before 
treatment is started. This makes ISSHL not only a neuro-otological but also a neuro­
radiological emergency. 
Chapter 8 describes the therapeutic value of the antiviral drug aciclovir (Zovirax®) on 
hearing recovery in 44 ISSHL patients receiving prednisolone as evaluated in a 
multicenter clinical trial. The study is designed prospectively, randomized, double­
blind and placebo-controlled. Subjective parameters include hearing recovery, 
tinnitus, a pressure sensation on the affected ear and disequilibrium or vertigo. 
Audiometric parameters include pure-tone and speech audiometry. A I year follow­
up is obtained. Tinnitus, occurring in a majority of patients, has a poor prognosis. 
Both the pressure-sensation and disequilibrium or vertigo have a favourable 
prognosis. Hearing recovery prognosis depends on the severity of initial hearing 
loss, and not on vestibular involvement. No beneficial effect from combining 
aciclovir with prednisolone on hearing recovery prognosis in ISSHL can be 
established, in contrast to our experimental findings (Chapter 6). Study results 
confirm earlier reports of a mild beneficial effect on hearing recovery prognosis from 
the early application of corticosteroids. Treatment aimed at the possible etiological 
agent might be benificial only in the very early phase of the hearing loss. However, 
no truly successful therapy can be offered to the ISSHL patient, because often, 
considerable hearing impairment remains. 
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Conclusions 
I .  ISSHL i s  a disabl ing disease. 
2. The incidence of ISSHL implies that a considerable number of patients suffer 
from ISSHL annually. 
3 .  A diagnostic protocol should b e  used when evaluating sudden sensorineural 
hearing Joss. This prevents diagnostic omissions. 
4. ISSHL should be treated within a multicenter clinical trial. 
5.  A subclinical viral labyrinthitis seems to play an important role in the 
pathophysiology of ISSHL. 
6. Herpes simplex virus type I labyrinthitis provides strong histopathological 
correlations with ISSHL. 
7 .  A synergistic therapeutical effect exists from combined treatment with anti­
inflammatory and antiviral medication on hearing recovery and histopathological 
cochlear damage in experimental herpes simplex type I viral labyrinthitis. 
8. ISSHL is both a neuro-radiological emergency and a neuro-otological 
emergency. A labyrinthitis can probably only be visualized on gadolinium 
enhanced MRI during the very early phase of hearing loss. 
9. Corticosteroids provide a limited beneficial effect on hearing recovery in ISSHL. 
This effect might be due to a limitation of cochlear damage by the attenuation of 
the cochlear inflammatory response. 
1 0. In our study design, intravenous aciclovir treatement of ISSHL has not been 
proven clinically beneficial. Theoretically and experimentally, this benificial 





Sinds het begin van deze eeuw zijn beschrijvingen bekend van ogenschijnlijk  
gezonde en  normaal horende personen die plotseling slechthorend of  doof worden. 
Ondanks de enorme vooruitgang in de medische wetenschap is dit ziektebeeld tot nu 
toe onbegrepen. In de meeste gevallen kan geen relatie tussen het plotselinge 
perceptieve gehoorverlies en een onderliggend ziektebeeld worden gelegd en spreekt 
men van idiopathisch plotseling perceptief gehoorverlies (Eng: Idiopathic Sudden 
Sensorineural Hearing Loss, ISSHL). De pathofysiologie van ISSHL blijft tot op 
heden onopgehelderd en een doeltreffende behandeling ontbreekt. 
Er bestaat geen populatie met een verhoogde kans op het ontwikkelen van ISSHL. 
Omstandigheden waardoor het gehoorverlies zou kunnen worden geluxeerd zijn erg 
moeilijk aan te geven: het gehoorverlies wordt niet zelden bij het opstaan bemerkt. In 
onze patientenpopulatie deed zich bij 30% van de gevallen een bovenste 
luchtweginfectie in de maand voorafgaande aan het gehoorverlies voor, hoewel het 
ontstaan van ISSHL niet seizoengebonden blijkt te zijn. 
Meestal treedt het gehoorverlies enkelzijdig op, incidenteel zijn beide oren 
aangedaan. Spontaan herstel van het gehoor wordt beschreven in 45-65% van de 
gevallen, alhoewel in een minderheid van de patienten een functioneel rest-gehoor 
overblijft. Herstel van het gehoor is afhankelijk van de ernst van het initiele 
gehoorverlies: is dit zeer ernstig, dan is de prognose somber, is dit mild of matig dan 
is de prognose minder ongunstig. Mogelijke andere prognostische factoren zijn 
betrokkenheid van het evenwichtsorgaan bij het gehoorverlies en de vorm van het 
audiogram, alhoewel deze laatste factoren niet door ons onderzoek konden worden 
bevestigd. Vrijwel aile patienten klagen over oorsuizen. Het persisteren van dit 
oorsuizen blijkt op de langere termijn naast het slechte gehoor een van de grootste 
problemen na ISSHL te vormen. Doorgaans voelt men een wat drukkend of pijnlijk 
gevoel rond en in het oor hetgeen soms rond het oor uitstraalt. Bij enkele patienten 
persisteert deze sensatie en neemt zij toe onder invloed van inspanning of stress. Het 
ontstaan van het gehoorverlies gaat vaak gepaard met evenwichtsstoornissen, 
varierend van een Iicht gevoel in het hoofd tot een heftige draaisensatie waarbij het 
onmogelijk is recht te !open. De prognose van deze evenwichtsstoornissen is in het 
algemeen op korte termijn gunstig. 
Twee eigenschappen van ISSHL bemoeilijken het onderzoek naar de ontstaanswijze 
en behandeling. Ten eerste is het binnenoor zeer kwetsbaar en daardoor moeilijk 
toegankelijk voor onderzoek. Ten tweede is, gezien het percentage spontaan herstel ,  
een grote serie waarnemingen nodig om conclusies te kunnen verbinden aan 
empirisch onderzoek. Hiervoor komt het ziektebeeld niet vaak genoeg voor. 
Literatuuronderzoek naar idiopathisch plotseling perceptief gehoorverlies wordt 
bovendien bemoeilijkt door het ontbreken van een eensluidende definitie. In dit 
proefschrift wordt de volgende definitie voorgesteld: 
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1 .  Perceptief gehoorverlies 
2. Oorzaak gehoorverlies kan niet worden gei'dentificeerd na klinisch, 
beeldvormend en laboratoriumonderzoek. 
3. Gehoorverlies is opgetreden binnen 24 uur 
4. Gehoorverlies fluctueert niet 
5. Ernst gehoorverlies is gemiddeld tenminste 30 dB HL 
voor 3 of meer octaafstappen in het standaard toondrempel audiogram 
6. Blanco otologische voorgeschiedenis. 
Deze definitie van ISSHL vertoont sterke overeenkomsten met diagnostische criteria 
die worden toegepast door een meerderheid van de KNO-artsen in Nederland en 
Vlaanderen (hoofdstuk 4). 
De genoemde beperkingen komen naar voren in het literatuuroverzicht over de 
etiologie van ISSHL (hoofdstuk 2) en de behandeling van ISSHL (hoofdstuk 3). 
In hoofdstuk 2 wordt de mogelijke etiologie van ISSHL besproken. Een viertal 
hypotheses met betrekking tot de pathofysiologie van idiopathisch plotseling 
perceptief gehoorverlies worden in de literatuur genoemd: 
1 .  Labyrinthaire doorbloedingsstoornis 
2. Subklinische virale labyrinthitis 
3. Spontane labyrinthaire membraanruptuur 
4. Autoimmuun labyrinthitis 
Deze veronderstellingen worden -in meerdere of in mindere mate- ondersteund door 
een vijftal bewijscategorieen: klinische gegevens, bevindingen bij laboratorium- en 
bij beeldvormend onderzoek, post mortem histopathologie en dierexperimentele 
studies. Deze bewijscategorieen worden voor iedere etiologische hypothese 
beoordeeld, waarbij de gehanteerde definitie van ISSHL wordt meegewogen. 
Geconcludeerd wordt dat onvoldoende aanknopingspunten bestaan om de primaire 
labyrinthaire doorbloedingsstoornis of de spontane labyrinthaire membraanruptuur 
verantwoordelijk te stellen voor ISSHL. Ook voor de autoimuun labyrinthitis worden 
onvoldoende aanwijzingen gevonden. Voor een subklinische virale labyrinthitis als 
veroorzaker van ISSHL worden veelbelovende, zij het indirecte aanwijzingen 
gevonden. Deze hypothese wordt in dit proefschrift nader uitgewerkt. 
In hoofdstuk 3 wordt de literatuur met betrekking tot de behandeling van ISSHL 
geevalueerd. De opzet van deze studies wordt beoordeeld op vergelijkbaarheid en op 
interne en externe validiteit. Daarbij wordt de gehanteerde definitie van ISSHL 
geverifieerd. Behandeling van ISSHL is veelal gericht op het optimaliseren van de 
mogelijk gecompromitteerde cochleaire bloeddoorstroming of op het remmen van 
een eventueel onderliggend ontstekingsproces. Voor behandeling van ISSHL met 
plasma-expanders, met vaatverwijdende middelen of met ontstolling wordt geen 
wetenschappelijke basis gevonden. Enkele studies wijzen op een beperkt gunstig 
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effect van corticosteroldbehandeling op de prognose van ISSHL. Een restgroep van 
andere behandelingsvormen is nog onvoldoende grondig onderzocht. Gezien het 
relatief hoge percentage spontaan herstel van ISSHL vergt het aantonen van een 
therapeutisch effect relatief grote aantallen patienten. De incidentie van ISSHL Iaat 
dit vaak niet toe. Daarom wordt aanbevolen behandeling van ISSHL te doen 
plaatsvinden in een multicentrische klinische trial. 
In hoofdstuk 4 wordt beschreven hoe men in de dagelijkse Nederlandse en Vlaamse 
KNO-praktijk omgaat met ISSHL, aan de hand van de resultaten van een enquete 
onder 230 Nederlandse en 50 Vlaamse KNO-artsen. Hierin is gelnformeerd naar 
definitie, voorkomen, diagnose, behandeling en mogelijke ontstaanswijze van ISSHL. 
Diagnostische criteria voor ISSHL komen goed overeen met de door ons gehanteerde 
definitie van ISSHL. De incidentie van ISSHL bedraagt 8/100.000 in Nederland en 
1 4,61100.000 in Vlaanderen. Verschillen in incidentie van ISSHL lijken afhankelijk 
te zijn van het stringent hanteren van diagnostische criteria. Een grote variabiliteit 
wordt aangetroffen in diagnostiek en behandeling van ISSHL tussen individuele 
KNO-artsen en tussen Nederlanders en Vlamingen. 
De diagnostiek bij het symptoom plotseling perceptief gehoorverlies vertoont 
belangrijke omissies. Hierdoor ontstaan hiaten bij het verifieren van de differentiaal 
diagnose van plotseling perceptief gehoorverlies. Het verdient daarom aanbeveling de 
ISSHL patient te screenen volgens een tevoren vastgelegd protocol. Corticostero"iden 
worden vaak toegepast bij ISSHL, maar ook vele andere behandelingsmodaliteiten 
worden, soms gecombineerd, toegediend alhoewel een duidelijke wetenschappelijke 
of empirische basis hiervoor ontbreekt. Behandeling van ISSHL wordt I 0 dagen na 
het ontstaan van het gehoorverlies niet Ianger zinvol gevonden. Het geschatte 
succespercentage van ISSHL behandeling komt overeen met de in de Iiteratuur 
genoemde percentages spontaan herstel .  Wellicht kan meer fundamenteel onderzoek 
naar de ontstaanswijze van ISSHL leiden tot verdere overeenstemming over etiologie 
en behandeling van ISSHL. 
In hoofdstuk 5 wordt een proefdiermodel van de pathogenese van ISSHL ontwikkeld, 
teneinde het inzicht in de pathofysiologie van ISSHL te verdiepen. De mogelijkheden 
hiertoe zijn bij de mens zeer beperkt (hoofdstuk 7) vanwege de kwetsbaarheid van het 
binnenoor. Bij het ontwikkelen van een proefdiermodel van ISSHL wordt uitgegaan 
van een subklinische virale labyrinthitis als oorzaak voor ISSHL. Uit eerder 
dierexperimenteel onderzoek naar de virale labyrinthitis blijkt een specifieke affiniteit 
te bestaan voor verschillende cochleaire structuren door verschillende virus-families. 
Deze patronen van cochleaire beschadiging wordt vergeleken met gedetailleerde 
beschrijvingen van de histopathologie van ISSHL. Deze blijkt sterk overeen te komen 
met experimentele virale labyrinthitis veroorzaakt door herpes virussen. In het 
proefdiermodel wordt via perily�pfatische inoculatie een subklinische herpes simplex 
type I (HSV-1 )  labyrinthitis ge!nduceerd bij de cavia, terwijl een controlegroep aileen 
het kweekmedium ontvangt. Primaire inoculatie wordt bevestigd door het bepalen 
van herpes antilichamen. Controle van gehoor- en evenwichtsfunctie v�ndt plaats. 
1 08 
Cochleaire histopathologie wordt beschreven aan de hand van Iicht- en elektronen 
microscopische beelden. Bij aile met HSV - 1  gei'noculeerde proefdieren treedt zeer 
snel na inoculatie gehoorverlies op terwijl de evenwichtsfunctie intact blijft. 
Behoudens seroconversie worden geen andere manifestaties van HSV - 1  infectie 
aangetroffen. Bij de controlegroep treedt gehoorverlies noch seroconversie op. Een 
vergelijking van de cochleaire histopathologie van experimentele HSV - 1  labyrinthitis 
met de histopathologie van ISSHL Ievert sterke overeenkomsten op: degeneratie van 
de stria vascularis, destructie van het orgaan van Corti, elevatie van de tectoriaal 
membraan en inflanunatoire veranderingen in neurale cochleaire structuren. 
Geconcludeerd wordt dat gebaseerd op overeenkomsten in histopathologische 
karakteristieken en klinische eigenschappen, experimentele HSV -1 labyrinthitis een 
geschikt model vormt voor ISSHL. 
In hoofdstuk. 6 wordt de invloed van behandeling van experimentele HSV- 1 
labyrinthitis in de cavia met de ontstekingsremmer prednisolon en het antivirale 
geneesmiddel aciclovir (Zovirax09) beschreven. Experimentele HSV - 1  labyrinthitis in 
de cavia vormt een geschikt pathofysiologisch model voor ISSHL (hoofdstuk 5). In 
de klinische setting verbetert het toedienen van corticosteroi'den de prognose van 
ISSHL. De waarde van aciclovir voor de behandeling van ISSHL is onbekend. In dit 
experiment wordt bij 12 cavia's een virale labyrinthitis met HSV- 1 gei'nduceerd. Drie 
dieren worden niet behandeld, 3 ontvangen prednisolon, 3 ontvangen aciclovir en 3 
ontvangen de combinatie aciclovir-prednisolon. De gehoorfunctie wordt 
gecontroleerd en herpes-antilichamen worden bepaald. Cochleaire schade wordt 
gei'nventariseerd door middel van lichtmicroscopie. Het toedienen van 
corticosteroi'den leidt tot herstel van de gehoorfunctie en tot beperking van cochleaire 
schade. Het toevoegen van aciclovir leidt tot eerder gehoorherstel en tot verdere 
beperking van cochleaire beschadiging, in vergelijking met corticosteroi'den als 
monotherapie. De combinatiebehandeling lijkt derhalve een synergistisch effect te 
vertonen in de experimentele situatie. Aanbevolen wordt de resultaten te extrapoleren 
naar de klinische setting en de combinatiebehandeling prednisolon-aciclovir te 
toetsen bij ISSHL patienten. 
In hoofdstuk 7 wordt gepoogd de labyrinthaire pathofysiologie van ISSHL te 
bestuderen door middel van kernspintomografisch (MRI) onderzoek. Tot dusverre 
werd MRI onderzoek bij ISSHL voornamelijk toegepast om enkele meer centraal 
gelegen oorzaken, zoals bijvoorbeeld tumorprocessen in de cerebellopontine hoek of 
multiple sclerose uit te sluiten. Voor dit doe! is MRI onderzoek ook bij de door ons 
onderzochte patienten geschikt gebleken. 
Daamaast kan Gadolinium-enhanced MRI (Gd-MRI) onderzoek een subklinische 
labyrinthitis bij ISSHL aantonen. De sensitiviteit van deze waarneming is echter 
onbekend. De resultaten van Gd-MRI onderzoek van 27 ISSHL patienten worden 
beschreven. Bevindingen bij MRI onderzoek worden gerelateerd aan de ernst van het 
gehoorverlies, aan betrokkenheid van het evenwichtsorgaan bij de uitval van het 
gehoororgaan en aan het tijdsinterval tussen het ontstaan van het gehoorverlies en het 
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maken van de scan. In 1 geval werd intracoch1eair pathologische aankleuring 
gevonden, passend bij een labyrinthitis, in de overige gevallen trad dit niet op. 
A1hoewel de waarde van MRI onderzoek bij ISSHL voor het detecteren van 
onderliggende pathologie ook bij onze patienten wordt bevestigd, blijkt het aantonen 
van een subklinische labyrinthitis met behulp van Gd-MRI moeilijk te zijn. Een 
dergelijke aankleuring wordt rnisschien aileen in de zeer vroege fase na het ontstaan 
van het gehoorverlies gezien en zou bij onze patienten nog gedempt kunnen worden 
door de reeds ingestelde ontstekingsremmende behandeling. Aanbevelingen worden 
geformuleerd voor het onderzoeken van ISSHL patienten met behulp van MRI. 
Geadviseerd wordt tenminste T 1 gewogen opnarnen voor en na toediening van 
gadolinium contrast te maken. Daarnaast wordt geadviseerd om het tijdsinterva1 
tussen gehoorverlies en MRI zo kort mogelijk te doen zijn omdat anders het lange 
tijdsinterval en de reeds ingeste1de behandeling de labyrinthitis moeilijk detecteerbaar 
maken. Dit maakt ISSHL behalve tot een otologisch spoedgeval ook een 
radiodiagnostisch spoedgeval. 
In hoofdstuk 8 worden de resultaten van een prospectief, dubbelblind, 
gerandomiseerd onderzoek naar de toepassing van aciclovir versus placebo naast 
prednisolon bij ISSHL beschreven. In een multicentrische klinische trial worden 44 
ISSHL patienten behandeld met prednisolon, waarvan 22 patienten aciclovir 
ontvangen en 22 placebo. Als subjectieve uitkomstvariabelen worden herstel van het 
gehoor, oorsuizen, een drukgevoel op het oor en evenwichtsstoornissen door 
patienten gecategoriseerd. Als audiometrische uitkomstvariabelen worden 
toondrempel- en spraakaudiometrie bepaald. De follow-up bedraagt een jaar. Een 
meerderheid van de behandelde patienten ervaart subjectief gehoorverbetering, welke 
overeenkomt met gemeten verbeteringen in het toondrempelaudiogram. Tinnitus 
treedt frequent op na ISSHL en heeft een matige prognose. De prognose van 
drukgevoelens op het oor en van evenwichtsstoornissen zijn goed. Patienten met een 
zeer ernstig initieel gehoorverlies hebben een slechtere prognose met betrekking tot 
gehoorherstel in vergelijking met patienten met een mild of matig ernstig initieel 
gehoorverlies. Betrokkenheid van het evenwichtsorgaan bij het gehoorverlies blijkt 
niet van invloed te zijn op het gehoorherstel .  Behandeling met aciclovir naast 
prednisolon heeft geen gunstige invloed op het gehoorherstel na ISSHL, in 
tegenstelling tot onze bevindingen bij experimenteel onderzoek (hoofdstuk 6). 
Eerdere rapportages van een beperkt gunstig effect op het gehoorherstel door het 
toepassen van corticostero'iden worden in dit onderzoek bevestigd. Wellicht is 
behandeling tevens gericht tegen het mogelijk veroorzakende agens aileen zinvol is 
in de zeer vroege fase nadat gehoorverlies is opgetreden. 
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Conclusies 
I .  ISSHL is een invaliderende ziekte. 
2. De incidentie van ISSHL impliceert dat een aanzienlijk aantal patienten jaarlijks 
door dit ziektebeeld worden getroffen. 
3 .  Een diagnostisch protocol dient bij het symptoom plotseling perceptief 
gehoorverlies te worden toegepast. Dit voorkomt diagnostische omissies. 
4. ISSHL dient bij voorkeur te worden behandeld in een multicentrische klinische 
trial. 
5 .  Een subklinische virale labyrinthitis lijkt een belangrijke rol te  spelen in de 
pathofysiologie van ISSHL. 
6. Herpes simplex virus type 1 labyrinthitis vertoont sterke klinische en 
histopathologische overeenkomsten met ISSHL. 
7.  Een combinatiebehandeling bestaande uit anti-inflammatoire en antivirale 
medicamenten vertoont een synergistisch therapeutisch effect op het 
gehoorherstel en op de histopathologische cochleaire beschadiging in 
experimentele herpes simplex type I virale labyrinthitis. 
8. ISSHL is een neuroradiologisch spoedgeval, naast een neuro-otologisch 
spoedgeval. Een labyrinthitis kan waarschijnlijk aileen in een zeer vroege fase na 
het gehoorverlies worden gezien op gadolinium enhanced MRI. 
9. Corticosteroi'den hebben een gunstig effect op het gehoorherstel na ISSHL. Dit 
effect kan wellicht worden verklaard door een beperking van cochleaire schade 
door remrning van de cochleaire ontstekingsreactie. 
1 0. Intraveneuze aciclovir behandeling van ISSHL Ievert in ons onderzoek geen 
klinische voordelen op. Theoretisch en experimented bestaat dit voordeel aileen 
indien toegepast in de zeer vroege fase nadat het gehoorverlies is ontstaan. 
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